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DOSE DELIVERY USING THE RADIOLOGICAL PHYSICS CENTER LUNG PHANTOM 
Publication No.: ____________ 
Roman Repchak, M.S. 
Supervisory Professor: David Followill, PhD 
The effectiveness of the Anisotropic Analytical Algorithm (AAA) implemented in the Eclipse 
treatment planning system (TPS) was evaluated using the Radiological Physics Center 
anthropomorphic lung phantom using both flattened and flattening-filter-free high energy beams.  
Radiation treatment plans were developed following the Radiation Therapy Oncology Group and the 
Radiological Physics Center guidelines for lung treatment using Stereotactic Radiation Body 
Therapy. The tumor was covered such that at least 95% of Planning Target Volume (PTV) received 
100% of the prescribed dose while ensuring that normal tissue constraints were followed as well.  
Calculated doses were exported from the Eclipse TPS and compared with the experimental data as 
measured using thermoluminescence detectors (TLD) and radiochromic films that were placed inside 
the phantom.  The results demonstrate that the AAA superposition-convolution algorithm is able to 
calculate SBRT treatment plans with all clinically used photon beams in the range from 6 MV to 18 
MV. The measured dose distribution showed a good agreement with the calculated distribution using 
clinically acceptable criteria of ±5% dose or 3mm distance to agreement.  
These results show that in a heterogeneous environment a 3D pencil beam superposition-
convolution algorithms with Monte Carlo pre-calculated scatter kernels, such as AAA, are able to 
reliably calculate dose, accounting for increased lateral scattering due to the loss of electronic 
equilibrium in low density medium. The data for high energy plans (15 MV and 18 MV) showed 
very good tumor coverage in contrast to findings by other investigators for less sophisticated dose 
v 
 
calculation algorithms, which demonstrated less than expected tumor doses and generally worse 
tumor coverage for high energy plans compared to 6MV plans. This demonstrates that the modern 
superposition-convolution AAA algorithm is a significant improvement over previous algorithms 
and is able to calculate doses accurately for SBRT treatment plans in the highly heterogeneous 
environment of the thorax for both lower (≤12 MV) and higher (greater than 12 MV) beam energies.  
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Chapter 1 Introduction 
 
1.1 Introduction and Background  
The Radiological Physics Center (RPC) is a quality assurance office (QAO) funded by the 
National Cancer Institute (NCI) that is tasked to provide quality assurance services to institutions 
participating in clinical trials funded by NCI and its cooperative study groups. The RPC evaluates 
radiotherapy programs, develops protocols and QA procedures, and helps correct institutional 
deficiencies. The goal of the RPC is to make sure that prescribed radiation doses that are being 
delivered are clinically comparable, accurate and consistent.  
The RPC provides services to over 1,800 institutions (over 14,000 beams) in the United 
States and abroad. Over the past 44 years the RPC has developed an extensive Quality Assurance 
(QA) program that includes on-site audit and remote audit tools.
 
The on-site audits include dose 
measurements on therapy machines, review of patient dose calculations and quality control (QC) 
procedures, as well as interviewing the oncology staff. The remote audit tools consist of 
development and implementation of credentialing processes for participation in specific protocols, 
analysis of patient dose calculations, and verification of beam calibration. Anthropomorphic QA 
phantoms employing optically-stimulated luminescence or thermoluminescence dosimeters 
(OSLD/TLD) and radiochromic film are used to verify the actually delivered doses and compare 
them to doses calculated by the Treatment Planning Systems (TPS). Additionally, the RPC helps 
institutions in identifying the sources of inconsistencies and works with them on corrective actions. 
The RPC’s remote audit QA program employs a multitude of different anthropomorphic 
phantoms, among which the pelvic-prostate, head-and-neck, and thorax phantoms are the most 
common. Each phantom is constructed in such a way that it would allow the RPC to test and evaluate 
if the institutions providing radiation therapy services are able to develop and deliver treatment plans 
that satisfy specific clinical trial protocol requirements. 
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The thorax (Lung) RPC phantom is used to verify dose delivery from two commonly used 
radiation therapy techniques: 3D conformal (3D CRT) and intensity-modulated (IMRT). It represents 
a hollow plastic case shaped as a human thorax that fills with water. The phantom contains specific 
structures simulating human organs, such as heart, spine, lungs, and tumor [1].  
Two types of dosimeters are used within the lung phantom: TLD for point dose and 
radiochromic film for two-dimensional dose distribution measurements. After an institution, that 
requests credentialing, irradiates the phantom, it is shipped back to the RPC for analysis. The data, 
measured by the dosimeters inside the phantom, is compared to the calculated values that are 
provided by the institution as well as to RPC established dosimetric parameters. This remote audit 
phantom QA program provides a reliable and cost effective tool in evaluating the institution’s 
abilities to develop and deliver a specific radiation treatment in order to participate in cooperative 
group trials. Furthermore, the program helps institutions to identify potential problems in their 
treatment process.  
The reproducibility of results with the thorax phantom, as described by Followill et al, 
proved its effectiveness in the credentialing process, making it very useful as an all encompassing 
test of the entire heterogeneity calculation algorithm of different TPSs [1, 2]. 
1.2 Statement of Problem 
As reported by Mah & Van Dyk [3], calculated doses that were not corrected for 
heterogeneities resulted in the radiation pneumonitis risk underestimates of up to 19%. They 
concluded that heterogeneity corrections should be used in all multi-center clinical trials to determine 
correct dose in each case. 
When high energy photon beams enter the air in the lungs the electron range in the lateral 
direction is increased which results in a loss of electronic equilibrium along the central axis [4]. 
Earlier studies that measured doses calculated with the algorithms that do not take into account the 
increased lateral scatter [5] advise against the use of small field sizes and high energy beams (18 
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MV) in heterogeneous environments such as the thorax and recommend selecting a lower beam 
energy (6 MV) when developing plans and calculating doses to a tumor surrounded by lung tissue.  
Due to dose escalation and high dose gradients in modern delivery techniques such as IMRT 
or Stereotactic Radiation Body Therapy (SBRT) for lung tumors, it is becoming increasingly 
important to correct for such heterogeneities. Heterogeneity dose calculation corrections in many 
contemporary planning systems use different dose calculation algorithms that are based on 
superposition-convolution models with pre-calculated Monte Carlo (MC) kernels. Techniques that 
take into account electron disequilibrium due to increased lateral electron scattering in low density 
medium result in dose calculations that are in better agreement with measured dose distributions and, 
therefore, should be used in place of those that ignore lateral scattering component (such as pencil 
beam superposition) [6].  
The superposition-convolution calculation typically has two components: first is the energy 
distribution that is released in the medium at the interaction site and the second component (kernel) 
represents the scatter distribution from this interaction. The latter component is typically obtained 
either analytically or by using Monte Carlo simulations. The superposition-convolution algorithm by 
itself integrates the first element (energy distribution at the primary interaction site) and second 
element (3D scatter distribution) over the entire body volume. The dose calculation in this case 
becomes a function of the algorithm itself, the geometry and the number of beams, as well as the 
resolution of the dose calculation grid [7]. 
 According to the RPC data based on their remote audit QA program’s TLD and 
radiochromic film measurements in anthropomorphic thorax phantoms, the heterogeneity corrected 
tumor doses calculated by different TPS in the lungs result in a wide range of delivered doses with 
Monte Carlo based methods having the best agreement with actual measurements [8, 9]. Even 
though heterogeneity correction of MC-based dose calculations are superior to the currently 
implemented superposition-convolution algorithms, Monte Carlo based techniques are largely 
impractical for clinical use due to substantial computational resources and time requirements.  
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While most dose calculation algorithms work well in a homogeneous medium they have 
been shown to not work well under certain specific, more challenging situations, such as higher 
photon beam energies and small field sizes. A Monte Carlo simulation study that looked into the 
differences between doses delivered using 6 MV and 15 MV energies [10] found that lower energy 
(6 MV) was preferable for lung cancer treatment to the MC simulated 15 MV beam since the latter 
resulted in a considerable loss of lateral equilibrium and significantly worse target coverage of 
planning treatment volume (PTV). One of the more recent studies that looked into the effectiveness 
of one of the modern superposition-convolution algorithms, Analytical Anisotropic Algorithm 
(AAA), implemented in the Varian Eclipse treatment planning system found that compared to Monte 
Carlo a 10 MV beam dose distribution in lung calculated by the AAA was inferior, while 6 MV 
beam resulted in an  accurate dose calculation with much better agreement [11] highlighting 
potential difficulties that even the most up-to-date dose calculation algorithms face when used to 
plan treatments with tumors inside of the lungs utilizing  high energy beams (>12 MV) and small 
fields. Due to complexities with accurate dose calculation in such conditions, at present, the SBRT 
lung treatments are performed using multiple fields (not less than 7) and beam energies of less than 
10 MV. It has been shown [11] that in most clinical situations the superposition-convolution 
algorithms that account for 3D scatter have proven to be adequate for use in radiation treatment 
planning. 
As was mentioned earlier, the Varian Eclipse TPS employs the Analytical Anisotropic 
Algorithm for volumetric heterogeneity corrected dose calculations. New data from the Radiological 
Physics Center (February, 2011) obtained using AAA in RPC’s Lung phantom showed excellent 
agreement (0.98 measured-to-predicted ratio for point dose using TLDs and 100% pixel pass rate 
using ±5%/5mm gamma index for planar dose distribution using films) for a lung treatment using 15 
MV x-ray beams. These data suggest that recent development in the AAA algorithm may have 
improved the volumetric heterogeneity corrected dose calculation so that it is now possible to use 
this algorithm for dose calculations in highly heterogeneous medium (such a lung) with beam 
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energies greater than 10 MV with dosimetric results that, prior to that, were only possible with 6 MV 
beams. 
1.3 Anisotropic Analytical Algorithm 
The Eclipse treatment planning system designed by Varian Medical Systems (Palo Alto, CA) 
was first introduced in 2001 and since then has been constantly evolving and adding many new 
features including intensity-modulated, image-guided, and arc radiation therapy, radiosurgery 
capabilities, conformal optimization, biological optimization and evaluation and many more. The 
planning system is capable of generating treatment plans using photon, electron, and proton beams 
making it one of the most popular commercially available TPS around the world with estimated over 
10,000 systems being deployed.  
The AAA essentially is a 3D pencil beam superposition-convolution algorithm. It employs 
separate Monte Carlo calculated models for primary and scattered extra‐focal photons, as well as for 
the electrons scattered from the collimators. A total of six exponential functions are used in its model 
to calculate the dose distribution in the lateral direction. This allows the use of analytical convolution 
in the algorithm greatly reducing calculation time. The AAA has been originally implemented in 
stereotactic radiation therapy planning and later was included in Eclipse TPS [12]. 
Clinically the AAA is separated into two individual components: configuration and dose 
calculation. The first part is designed to acquire the necessary fundamental parameters of the clinical 
beam, i.e. energy spectra, photon and electron fluence, which are later used for the actual dose 
calculation. To account for complex composition of clinical beam, the AAA uses multiple sources to 
model the beam with only primary photons being considered primary source. Scattered and extra-
focal photons along with electrons are treated as separate secondary sources. 
To model the primary source, the AAA employs a phase space model that uses physical 
parameters obtained during the commissioning process. To determine the energy spectrum, the 
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algorithm takes into account the flattening filter characteristics and the beam mean energy 
dependence on the radial distance from the central axis. The secondary source model employs a 
virtual source that is located at the exit point of the flattening filter and includes an energy spectrum 
which is scaled to achieve a specified mean energy without any off-axis variations.  
The original scatter kernels are obtained from the Monte Carlo pre-calculated data, but they 
also can be acquired from the energy spectrum during the configuration step of the algorithm. The 
scatter kernels provide the information on scatter characteristics for different beams. Since the actual 
beam is polyenergetic, multiple monoenergetic kernels were calculated in water using the Monte 
Carlo method from which the polyenergetic kernel is created as a weighted sum of the specific set of 
these kernels. In actual dose calculation, scaling accounts for differences between water density and 
the densities obtained from computed tomography (CT) simulated images. The clinical beam is 
divided into many finite-size beamlets with multiple convolutions performed for primary and 
secondary sources and the final 3D dose calculation is completed by superposing the beamlets [12]. 
The heterogeneity correction in the AAA has two components: the lateral scatter and the 
depth-directed component. Modeling of the lateral component using exponential functions provides 
an accurate representation of lateral scatter in a heterogeneous environment. The depth-directed 
component represents the total deposited energy, calculated using the lateral scatter functions on 
each plane. The convolution of this component accounts for tissue interface effects. With enough 
distance from the low-high density interface the AAA calculated results are comparable to Monte 
Carlo simulations. As was mentioned earlier, this technique has some limitation in treatment 
planning in lungs involving small field sizes and higher energies due to loss of electronic equilibrium 
along the central axis [13]. Improvements have been made to the AAA dose calculation algorithm in 
the area of tissue heterogeneity modeling and the accuracy of the scattered dose calculation making 
the AAA one of the most accurate commercially available non-MC-based algorithms at this time.   
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1.4 Hypothesis and Specific Aims 
The hypothesis of this research is: 
There will NOT be a difference of greater than ± 5% or 3 mm distance to agreement 
(DTA) on average between radiotherapy treatments using 6 MV beam and energies greater 
than 10 MV using flattened and flattening filter free (FFF) photons beams as measured 
with the RPC’s Lung phantoms.   
 
The specific aims of this work are: 
1. Create clinically relevant 6x/18x, and 6x/15x, 6x/10x FFF (TrueBeam) SBRT 
treatment plans for the RPC Lung phantom from a typical prescription and dose 
constraints for flattened and FFF beams. 
2. Compare the flattened and FFF treatment plans to the respective higher energies 
plans to determine if they are clinically comparable. 
3. Deliver 3 planned treatments to the RPC Lung phantom for each developed plan 
and measure the dose distribution from each. 
4. Compare the measured and calculated doses delivered by flattened and FFF beams 
using clinically acceptable criteria 90% of points passing ±5%/3mm gamma index 
for 2D dose distribution and ±5% for point dose. 
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Chapter 2 Methods and Materials 
  
2.1 The RPC Anthropomorphic Thorax Phantom 
2.1.1 Design and Construction  
The phantom used in this study was the RPC Lung Phantom #23. It is commonly used by the 
RPC as a remote QA tool. The primary use of this phantom is for credentialing institutions who 
intend to take part in clinical trials for the treatment of lung tumors supported by the NCI.  In order 
to create a realistic clinical scenario the phantom was created to simulate the major anatomical 
structures of the thoracic cavity, such as chest wall, heart, spine, and lungs with a tumor inside of the 
left lung. All the structures are made of material with similar radiological properties to that of the 
human body, such as material density, CT number, and effective atomic number. Table 2.1 contains 
the characteristics of the materials used in the phantom. The body of the phantom is made of half a 
centimeter polyvinyl chloride (PVC) that creates a hollow case that is filled with water during CT 
simulation and dose delivery. This construction allows the phantom to be relatively light when not in 
use and drained of water. At the same time, water that fills the phantom has comparable radiological 
characteristics to that of the surrounding soft tissues. The structures that represent major organs have 
simplified shapes such as the spherically shaped heart located in the center of the phantom. The spine 
is represented by a cylinder located posterior-medially, and the tumor is in the shape of rounded 
cylinder. The external dimensions of phantom (including edges) are 39 cm in length, 41 cm in width, 
and 27 cm / 32 cm in height (front/back).  The target (tumor), located in the center of the left lung, is 
divided into two equal superior and inferior parts with the overall dimensions 3 cm in diameter and 5 
cm in length.   
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Table 2.1 RPC Phantom Material Densities and CT Numbers 
Phantom Structure Substitute Material 
Density     
[g / cm3] 
Material CT 
Number [HU] 
Phantom Shell PVC 1.37 630 
Tumor HIPS 1.04 -50 
Lung Insert Compressed Cork 0.33 -640 
Lungs CIRS Lung (Inhale) 0.21 -660 
Heart Nylon 1.08 97 
Spine Acrylic 1.17 230 
 
Four TLDs and three orthogonal radiochromic films are used to verify the accuracy of the 
dose delivered during each phantom irradiation. Two TLDs, labeled HEART_TLD and 
CORD_TLD, one for heart and one for spine, respectively, are placed inside two acrylic rods and 
inserted in their respective anatomical location holes in the phantom to position the heart TLD 
superior to the target and the spine TLD inferior to tumor.  
The target, made of high impact polystyrene, is embedded inside of a separate insert made of 
compressed cork that is enclosed in the plastic cylindrical housing. The housing has a hole at the 
bottom that serves as a key when it is fully inserted into the phantom and prevents it from moving. 
The housing can be disassembled by unscrewing two top plastic screws and removing handle and lid. 
This insert represents the posterior part of the left lung and consists of two parts. The tumor inside of 
this imaging/dosimetry insert is also divided into superior and inferior parts. Each part of the target 
has an opening ~3mm off of the center of the target for its own TLD, labeled PTV_TLD_sup and 
PTV_TLD_inf. TLDs were used for absolute dose measurement and are described further in chapter 
2.6.3. Two-dimensional dose distributions were measured using radiochromic films (chapter 2.5.1). 
Three orthogonal slots for radiochromic films are made in the axial, coronal, and sagittal directions 
inside of the imaging/dosimetry insert and tumor.  The coronal and sagittal films have ~ 2 cm long 
central cuts that allow them to be inserted perpendicular to each other inside the target. Both films 
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are also cut in half into superior and inferior pieces. This allows the axial film to be placed between 
the superior and inferior films and target TLDs and in the middle of the two halves of the insert 
(Figure 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Orthogonal Film Arrangement Inside The Phantom Insert 
 
Coronal 
Sagittal 
Axial 
Sagittal 
Coronal 
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After all TLDs and films were placed in their proper positions the two parts of the 
imaging/dosimetry insert are put into the plastic housing, the lid is closed, and the handle is screwed 
back in. The plastic housing has eight side holes and three holes on top of the lid that are used for 
film registration. In order to know the exact position of the films a sharp metal pin was used to make 
a four registration pricks in each coronal and sagittal film through the housing side holes and three 
pricks through the lid in the axial film before the superior part of the insert was lowered in the plastic 
housing. After the imaging/dosimetry insert was assembled it was placed inside the phantom and 
keyed into place to prevent any movement. Figure 2.2 shows two heart and spine TLD inserts, as 
well as the open target insert removed from the housing. Figure 2.3 shows a fully assembled 
phantom.  
 
Figure 2.2 Heart And Spine TLD Inserts With The Open Target Insert 
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Figure 2.3 A Fully Assembled RPC Lung Phantom 
2.1.2  CT Simulation of the RPC Phantom 
CT simulation is a process of imaging the patient or phantom with the goal of using the 
obtained series of axial images in the treatment planning process. For the purpose of this study, the 
RPC phantom was scanned on an AcQSim 2 CT scanner (Philips Medical System, Bothell, WA). 
Simulation localization is the process of aligning the center of the phantom with the two lateral and 
sagittal CT localization lasers. In order to remain consistent, the location of the lasers on the 
phantom (LAP of America LC, Boynton Beach, FL) employed during CT simulation were the same 
as those used during the dose delivery in the linear accelerator vault. During the localization step the 
phantom was marked at the cross-section of the three pairs of lasers with small fiducial markers 
(metal spheres ~3mm in diameter). These markers are routinely employed in most clinical cases to 
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help establish the center of coordinate in the patient or phantom during the planning process (chapter 
2.3). After the phantom was set up and aligned on the table, it was scanned using a typical clinical 
protocol for thoracic cancer patients: 120 kVp, 383 mAs, pitch of 1, 1.5 mm slice thickness, and 500 
mm Field of View (FoV). A total of 410 axial CT images were acquired and transferred to Eclipse 
TPS for planning (Figure 2.4). 
 
Figure 2.4 An Axial CT Slice Of The Phantom That Contains The Target. Fiducials, Marked With 
Arrows, Can Be Seen On The Phantom Surface 
2.2 Treatment Planning 
2.2.1  SBRT Plans: Dose Prescription and Limits 
The SBRT plans were designed according to the “Guidelines for Planning and Irradiating the 
RPC Lung Phantom” (March 2010 Revision) [14]. Three critical organs at risk were contoured in 
the Eclipse TPS – lung (left and right), heart, and spine. The spine was contoured 10 cm above and 
below the PTV and the body contour was expanded by 0.5 cm according to various RTOG protocols 
(Table 2.2). Per the RPC instructions [14] and RTOG protocols [15, 16, 17, 18] the Clinical Target 
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Volume (CTV) was equal to Gross Tumor Volume (GTV). The Planning Target Volume (PTV) was 
created by expanding the GTV by 0.5 cm axially and by 1 cm in superior-inferior direction.  
Table 2.2 RPC/RTOG List Of SBRT Lung Treatment Protocols 
 RPC – 03/10 RTOG 1021 – 
05/11 
RTOG 0915 – 
08/10 
RTOG 0813 – 
02/10 
RTOG 0618 – 
02/09 
Dose (Gy) x 
frac 
6 x 1 18 x 3 34 x 1,  
12 x 4 
10 x 5 20 x 3 
CT Scan  
Slice, mm 
Lung 
≤3mm 
Lung 
≤3mm 
Lung 
≤3mm 
Lung 
≤3mm 
Lung 
≤3mm 
Static beams 
(min. recom’d) 
7 
≥10 
7 
≥10 
7 
≥10 
7 
≥10 
7 
≥10 
Arc, angle >340° >340° >340° >340° >340° 
Energy, MV 4-10 4-10, 10-15 
<50% beams 
4-10, 10-15   
≤2 beams 
4-10, 10-15   
≤2 beams 
4-10, 10-15    
≤2 beams 
PTV V95% Dx 100% 100% 100% 100% 100% 
PTV V90% Dx >99% >99% >99% >99% >99% 
Spillage (NT)  >105% Dx 
<15% PTV 
>105% Dx 
<15% PTV 
>105% Dx 
<15% PTV 
>105% Dx  
<15% PTV 
Conformality 
Index 
 <1.2 
Protocol spec. 
<1.2 
Protocol spec. 
<1.2 
Protocol spec. 
<1.2 
Protocol spec. 
Field size/shape PTV PTV PTV PTV PTV 
Spinal cord Any point  
≤5Gy 
Protocol spec. Protocol spec. Protocol spec. Protocol spec. 
Heart 
(%volume 
receiving X 
Gy) 
<33% - ≤6 
Gy 
<66% - ≤4.5 
Gy 
<100% - ≤4 
Gy 
Protocol spec. Protocol spec. Protocol spec. Protocol spec. 
Lungs 
(%volume 
receiving X 
Gy) 
<37%- ≤2 Gy Protocol spec. Protocol spec. Protocol spec. Protocol spec. 
Contouring 
CTV GTV GTV GTV GTV GTV 
PTVaxial GTV+0.5 cm GTV+0.5 cm GTV+0.5 cm GTV+0.5 cm GTV+0.5 cm 
PTVlong GTV+1 cm GTV+1 cm GTV+1 cm GTV+1 cm GTV+1 cm 
D2cm  PTV + 2 cm PTV + 2 cm PTV + 2 cm PTV + 2 cm 
Spinal cord  10 cm above 
and below 
PTV 
10 cm above 
and below 
PTV 
10 cm above 
and below 
PTV 
10 cm above 
and below 
PTV 
Skin  Body + 0.5 cm Body + 0.5 cm Body + 0.5 cm Body + 0.5 cm 
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For the phantom irradiation, a single fraction of 6 Gy was prescribed and normalized to be 
delivered to at least 95% of the PTV.  The secondary dosimetric objective of 90% of the prescribed 
dose to at least 99% of the PTV was also met. Plans were verified to make sure that conformality 
indices (CI) were <1.2 according to the RTOG recommendation. A Dose Volume Histogram (DVH) 
was used to verify that the calculated doses to critical structures (spinal cord, heart, and lung) were 
below their corresponding limits specified for the RPC Lung phantom Table 2.3.  
Table 2.3 Normal Tissues Constraints (RPC Protocol) 
Normal structure Volume Dose 
Spinal Cord Any point 5.0 Gy 
Heart 
<33% total vol 
<66% total vol 
<100% total vol 
6.0 Gy 
4.5 Gy 
4.0 Gy 
Whole Lung 
(Right & Left) 
<37% total vol <2.0 Gy 
 
The four TLDs were contoured: CORD_TLD (spine), HEART_TLD (heart), PTV_TLD_sup 
(superior half of the target), and PTV_TLD_inf (inferior half of the target). These volumes were used 
to calculate the measured-to-predicted dose ratio and for dose correction in 2D film dose analysis 
(chapter2.6.3). 
A total of six phantom irradiation plans were developed. Two SBRT plans - 6 MV and 18 
MV - were designed to be delivered on the MD Anderson Varian Clinac 2100CD and 21EX linear 
accelerators (Varian Associates, Palo Alto, CA). The other four plans - 6 MV FFF, 6 MV, 10 MV 
FFF, and 15 MV – were created to be delivered on a Varian TrueBeam STx linear accelerator at The 
University of Alabama (UAB) at Birmingham Medical Center. 
2.2.2  SBRT Plans: 6 MV and 18 MV MDACC 
RPC instructions called for a minimum of 7 non-opposing static beams [14]. A total of nine 
beams were utilized in each of the six treatment plans at 25⁰, 60⁰, 115⁰, 150⁰, 180⁰, 220⁰, 260⁰, 285⁰, 
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and 345⁰ (Figure 2.5). To minimize the setup uncertainty, beams angles, couch, and gantry 
orientations were kept identical for all plans (Figure 2.6). 
 
Figure 2.5 3D View Of The Beam Arrangement Used In All Plans 
 
a)
 
b)
 
 Figure 2.6 Beams Configuration Used In a) 6 MV Plan (MDA) and b) 18 MV Plan (MDA) 
 
X and Y collimator jaws were fixed at 6.0 cm and 7.9 cm, respectively, and the multi-leaf 
collimator was aligned with the PTV borders. 
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Heterogeneity corrected dose calculations for the six treatment plans were performed using 
the AAA version 8.9.08 with a dose calculation grid size of 2.5 x 2.5 mm2.  
2.2.3 SBRT Plans: 6 MV FFF, 6 MV, 10 MV FFF, and 15 MV UAB MC 
After the 6 MV treatment plan was completed and verified it was exported from the research 
Eclipse TPS at MD Anderson Cancer Center to the clinical Eclipse TPS at the UAB Medical Center 
and recalculated using UAB MC TrueBeam 6 MV beam model. A 15 MV plan was created and 
recalculated using the same 6 MV primary and secondary dose objectives. The flattening filter 
(Figure 2.7) was in place for the 6 MV and 15 MV beams plans, but it was removed for the 6 MV 
FFF and 10 MV FFF configurations. The UAB plans were recalculated with a small isocenter shift, 
as compared to the MD Anderson plans, to simplify the setup in new geometry of the TrueBeam STx 
linear accelerator. 
 
Figure 2.7 Varian Linear Accelerator Head Components 
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Flattening-filter-free beams have a lower effective energy as well as a beam profile that, 
unlike a flattened beam, peaks in the middle. This profile shape along with the increased beam 
output (by 2-4 times) makes FFF very efficient in treatment of small targets using stereotactic 
radiosurgery (SRS) and SBRT [19]. Additionally, removal of the flattening filter leads to a reduction 
in linear accelerator head radiation leakage by more than half and results in overall lower peripheral 
doses to the patient, which is even more substantial for higher energies [20]. 
2.3 Treatment Plan Delivery 
2.3.1 MD Anderson Cancer Center 
As was mentioned in chapter 2.2.1, 6 MV and 18 MV plans were delivered to the phantom at 
the MD Anderson Cancer Center using Clinac 2100CD (Rm 2104) and Clinac 21EX (Rm ACB3).  
These dosimetrically matched linear accelerators used Millennium 120 multi-leaf collimators 
(MLC). MLC files for both plans (6 and 18 MV) were loaded on the accelerator treatment computer. 
The alignment of the phantom was performed using the installed treatment room laser system 
identical to the one installed in the CT simulation room. After the alignment was complete the couch 
was shifted 8.8 cm to the right, 4.2 cm in anterior, and 0.5 cm in superior direction. This effectively 
moved the center of the target to the machine isocenter according to Eclipse calculated distances. 
Every beam was delivered in service mode using beam parameters calculated in Eclipse for a total of 
nine beams per plan. Each phantom plan irradiation was repeated three times. Films and TLDs were 
replaced with new ones after each irradiation for a total of 6 irradiation sets.  The beam data for 6 
MV and 18 MV are shown in chapter 2.2.2 (Figure 2.6).   
2.3.2 University of Alabama at Birmingham Medical Center 
A total of four plans, 6 MV FFF, 6 MV, 10 MV FFF, and 15 MV, were each delivered three 
times at UAB MC. The TrueBeam STx (S/N #1005) linear accelerator was capable of performing 
clinical flattening-filter-free irradiations and was commissioned for use with 6 and 10 MV FFF beam 
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energies. The TrueBeam STx linear accelerator also uses a new collimator system - high definition 
120 multi-leaf collimator (HDMLC). As was mentioned in chapter 2.2.3, the plans were recalculated 
using UAB commissioned beam models for each respective energy.  The plans were delivered in 
DICOM filemode. To ensure proper alignment of the phantom on the treatment table, an on-board 
imaging (OBI) system was employed in addition to using the lasers. During this imaging the 
unloaded phantom was used, so no extra dose from the OBI had to be accounted for. Once the 
phantom position had been confirmed, the insert was loaded with films, TLDs were inserted, and 
each plan was delivered. After each plan irradiation, a visual inspection of the films to confirm the 
correct phantom positioning was performed prior to another set of four plans being delivered, 
followed by the final, third set of irradiations of all four plans. Films and TLDs were replaced with 
the new ones after each irradiation for a total of 12 irradiation sets.   
2.4 Dosimetry 
2.4.1 Gafchromic® EBT2 Film  
 Radiochromic films are two-dimensional dosimeters with high spatial resolution and low 
spectral sensitivity variation. Their daylight sensitivity is minimal which allows them to be handled 
in well-lit rooms. These films change color directly in response to radiation and do not require any 
chemical processing. Image forms during a polymerization process, in which energy is transferred 
from the high energy photons or particles to the photomonomer molecule resulting in a chemical 
reaction that leads to color change [21]. Because of their excellent dosimetric characteristics and ease 
of use radiochromic films have been widely adopted and, along with TLDs, have been used by RPC 
for many years as an important remote audit tool in multiple generations of RPC phantoms and 
research. 
Radiochromic film used in this study was Gafchromic® EBT2 (Lot # A06271103, Exp. date: 
June, 2013) manufactured by Ashland (Covington, KY). EBT2 film is well suited for use in 
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dosimetry of radiotherapy beams because of its low energy dependence, high spatial resolution, 
negligible sensitivity to light, and no need for wet chemical processing. This film has a spatial 
resolution <0.1 mm and near-tissue equivalent density (Zeff 
EBT2
 =6.84). [22]. 
EBT2 film is a newer version of EBT film that has been improved in a couple of key areas. 
Yellow dye was added to minimize differences resulted from nonuniform film coating. It is less 
sensitive to day light and more resistant to damage when cut into pieces. It has very little energy 
dependence and can be used in an energy range from 50 keV to 20 MeV. EBT2 is made by 
combining clear layers of polyester with the active film coating that contains a chemical polymer 
[23]. A 175 micron-thick clear layer of polyester substrate is covered by a 30 micron-thick film of 
active layer and a 5 micron-thick topcoat. Finally, a 50 micron-thick protective layer of over-
laminate is glued to the layer of topcoat by a 25 micron thick adhesive layer (Figure 2.8).  
After exposure to radiation the active monomers in EBT2 film form a polymer that is visible 
to the naked eye with two absorption peaks at 585 and 636 nm. Due to film self-development the 
increase in optical density (OD) reaches 99% of its maximum after 2-3 days for films exposed to 1-15 
Gy [22]. Therefore all films were scanned 3 days post-irradiation to reduce the self-development 
effect. 
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Figure 2.8 Structure Of Gafchromic ® EBT2 Film (Not To Scale) [23] 
2.4.1.1  Film Preparation  
 EBT2 film used in this study came in an 8”x10” format with 25 sheets per box. Film was cut 
into multiple pieces according to the RPC templates. The axial film was cut to fit in the middle of the 
two halves of the target insert and marked with permanent marker at the opposite edges to indicate 
film orientation (Figure 2.9). Coronal and sagittal films were cut in half as was described in chapter 
2.2.1 (Figures 2.10 and 2.11) 
 
 
 
 
 
 
 
175 μm Polyester Substrate 
 
30 μm Active Layer 
5 μm Topcoat 
25 μm Adhesive Layer 
 
50 μm Polyester Overlaminate 
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Figure 2.9 Irradiated Axial Film With Registration Pricks 
 
 
Figure 2.10 Irradiated Coronal Film With Registration Pricks 
 
23 
 
 
Figure 2.11 Irradiated Sagittal Film With Registration Pricks 
 
In order to reliably relate ODs of the films to the dose, a dose response relationship between 
a known dose and fixed ODs was determined using the following method. A set of dose values were 
selected from the low and the high range of exposures. For this work a total of 8 dose values were 
selected to be delivered using 0.55, 1.64, 2.74, 3.83, 6.02, 8.21, 10.40, and 12.59 Gy. Two sheets of 
EBT2 film were cut into 8 equal (10 x 12.5 cm) pieces, each one marked with the corresponding 
dose it would receive. Figure 2.12 shows a standard setup for obtaining the dose response curve. 
Each piece of film was placed on top of 9 cm thick solid water phantom and covered with another 
1.5 cm thick block of solid water. The source-to-surface distance (SSD) was set at 100 cm and the 
field size was 35 x 35cm
2
. Placement and orientation of every film piece was consistent to avoid any 
directional uncertainties. A field size dependent output factor correction was applied to convert the 
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MU into dose. The dose response film irradiation and scanning were performed at the same time 
along with the RPC Lung phantom films (chapter 2.5.1.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 Phantom Used In Dose Response Film Irradiation 
2.4.1.2 Film Scanning  
Three days after irradiating the films, they were scanned on a transmission type 
microdensitometer PeC CCD100, S/N: 9101077328E (Photoelectron Corporation, North Billerica, 
MA). The scanner was located inside of a dark cabinet and consisted of 16 bit 512 x 512 pixel 
charged-coupled device (CCD) camera that could be moved vertically to accommodate different 
fields of view and a flatbed light source with compression transparent lid on which films were 
placed. According to the manufacturer, the light-emitting device inside of the scanner bed was 
Film 
1.5 cm solid water 
9 cm solid water 
SSD=100cm 
Source 
Field 35x35 cm2 
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specified at 665 nm which was a close match to one of the absorption peaks of the EBT2 film. This 
matching is important in order to maximize the signal-to-noise ratio due to CCD camera sensitivity 
to noise. 
After the CCD camera was set to the properly set, a focus scan was performed to verify the 
resolution of the camera. A black paper mask was used for the rest of the scans to limit the backlit 
area of the scanner bed to the effective area of films. Before films could be scanned a flatfield file 
was created using a blank sheet of non-irradiated film. This flatfield was used as a background and 
was subsequently subtracted from each film scan. A spatial calibration was performed using 
transparent sheet with a grid of known dimensions and a field of view of 200 x 200mm which 
resulted in 0.4 mm pixel size. Every film was read in the same orientation to avoid any possible 
inconsistency within the batch. 
During the scan the optical density (OD) of the film was converted into an electrical signal in 
the CCD camera. This signal was further digitized and digitally processed (including flatfield digital 
subtraction) and the final image was written into Flexible Image Transport System (FITS) file. This 
format was specifically designed for storage and transmission of scientific data and includes 
information about spatial calibration as well as other metadata that were used in the image analysis. 
An additional scanning of the dose response films was performed before the phantom films 
were scanned and average values for the large region of interest (ROI) for each piece of dose 
response film was recorded and verified. Obtained values were used to correlate the dose to OD 
(chapter 2.5.1.1). This was done by plotting Dose vs. OD and fitting third order polynomial dose 
response curve intersecting 0 on the Y axis. The fit coefficients of the dose response equation were 
imported into a configuration file of the MATLAB package used for the film analysis (chapter 
2.6.3).  
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2.4.2 Thermoluminescence Dosimeters 
Thermoluminescence dosimeters (TLD) are a vital tool for measuring the absolute absorbed 
dose in radiation therapy. As was mentioned in chapter 2.1.1, both films and TLDs have been 
extensively used in the RPC remote audits. Their cost, flexibility and ease of use have made them 
ideal dosimeters to be used. The total uncertainty due to random fluctuations was calculated to be 
±2.3% dose uncertainty with a 93% confidence interval equal to ±5% [24]. 
2.4.2.1 TLD Design and Placement  
To measure point doses inside the phantom a TLD-100 powder (batch B11) was used. The 
active component of TLD-100 is LiF powder doped with Mg and Ti that emits light while being 
heated in a TLD reader. Each “Double-load” TLD plastic capsule was 15mm in length and 4mm in 
diameter with 1mm thick walls. Each capsule was a two-compartment container with each 
compartment having about 15 mm
3
 of active volume that was filled with 20-22mg of TLD powder. 
TLD powder in each compartment was weighed and read individually and the final dose was 
calculated taking the average of the two readings. A total of 4 capsules were used in each irradiation 
(chapter 2.2.1) – two in superior and inferior tumor inserts and one in each heart and spine inserts. 
Since the TLD capsules were asymmetric due to one end being sealed, the placement of the TLDs 
was such that the plugged end of the capsule was facing away from the axial film in the tumor. For 
axial film TLD correction the calculated doses from both superior and inferior capsules were 
averaged. For coronal and sagittal films, only doses from their corresponding capsules were used 
such that superior capsule was used only for superior coronal and superior sagittal films and the 
inferior capsule – for inferior films only.  
2.4.2.2 TLD Dose Calculation 
TLD readout and dose calculation was performed according to the RPC “Procedure for 
Calculating TLD Doses” for batch B11 [25].  
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In TLD dose calculations it is important to know the dose-to-reading relationship. This was 
accomplished by using two sets of Standard TLDs irradiated to known doses. Each Standard TLD set 
consisted of 3 high (8 Gy) and 3 low dose (2 Gy) TLDs. The Standards were put inside a small 
Lucite phantom and placed in the center of a 10 x 10 cm
2
 irradiation field from a Theratron 780C 
Co
60
 machine. These Standards were read before the start of each session as well as at the end.  
In order to minimize random and systematic uncertainties during the readout process a total of 
four Control TLDs were read during each TLD reading session. Two Controls were read at the 
beginning (after the first set of Standards) and at the end of the session (before the second set of 
Standards). After each set of 6 phantom TLDs were read another set of Controls followed. This was 
done to make sure that session was consistent from the start to the end and that there weren’t any 
changes in the read sensitivity during the session. 
Thermoluminescence is a process that directly depends on the amount of the material being 
read. Since the mass of the TLD powder is variable in every capsule it had to be accurately 
determined prior to readout process. The mass was measured using analytical balance AT261 
DeltaRange (Mettler Toledo, LLC, Columbus, OH). Charge collected during the heating of the 
powder was recorded alongside with the powder mass from each capsule compartment to yield a 
normalized TLD reading in μC/mg units. Standard deviation of these readings from both 
compartments of the TLD capsule served as an indicator of how reliable was each normalized TLD 
dose.   
The dose calculated from the TLD readings is determined according to the following equation 
D = MTLD x S x KF x KL x KE 
Where 
D – represents dose to a muscle; 
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MTLD  – An average TLD reading per unit mass (mg); 
S – System sensitivity; 
 KF – Fading correction factor 
KL – Linearity correction factor 
 KE– Energy correction factor 
The System Sensitivity was determined for each session by dividing the expected Standard 
dose by MTLD, KF and KL. The energy correction for Co
60
 beam is 1. 
S = Dexpected/( MTLD x KF x KL ) 
Readout-to-dose response for TLD changes with time. To correct for differences in fading 
between phantom TLDs and Standards the following equation was used: 
,KF = N/(a  e
-bt
 + c  e-dt) 
Where 
t – Number of days passed from irradiation date. 
a, b, c, d, and N are empiric constants that depend on the TLD. For TLD batch B11 the RPC 
used the following values: 
 a = 1.2815 
 b = 0.00010885 
 c = 0.067810 
 d = 0.071908 
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 N = 1.3493 
 Thermoluminescence dosimeters tend to overrespond at higher doses resulting in a supra-
linear function. In order for the TLD readings to reliably represent the actual dose it has to be 
adjusted by a linearity correction factor KL. KL was calculated by irradiating multiple sets of three 
TLD capsules from 1 to 40 Gy using a 
60
Co machine. Readings from each set were averaged and 
adjusted for system sensitivity and fading correction factor as was described previously. The 
linearity correction factor KL was calculated as ratio of actual dose to the apparent dose and it was 
plotted against the apparent dose (Figure 2.13).  
 
Figure 2.13 Polynomial Fit Of KL Vs Apparent Dose Relationship For TLD Batch B11 
 
A second order polynomial fit based on the RPC’s batch B11 data resulted in the following fit 
coefficients: 
KL = a x Di
2
 + b x Di + c, 
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Where 
a = 2.552065 x 10
-8
; 
b = -2.221104 x 10
-4
; 
c = 1.064337 
And 
Di  – is estimated dose from the previous iteration, while D0 – being first approximation dose 
without linearity correction  
D0 = (MTLD x S x KF x KE) 
Linearity corrected dose was calculated for a total of six iterations multiplying D0 by the 
current iteration linearity correction factor KL.  
The energy correction factor, KE, is needed to correlate the Standard TLD response in Co
60
 
beam to the energies used in this work. KE takes into account specifics of the scatter medium of the 
phantom as well as spectral differences between Co
60
 beam and linear accelerator beams of different 
energies. The following values for energy correction were used for the RPC Lung phantom [26]. 
Energy, MV KE 
6 1.011 
10-12 1.023 
15-20 1.036 
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2.5 Data Processing and Analysis 
2.5.1 Plan Export 
For data analysis to take place the plans designed in Eclipse TPS were exported using the 
Export Wizard (Figure 2.14) tool. 
Every plan was exported using Digital Imaging and Communications in Medicine (DICOM) 
format and included a full set of CT images, defined structures, and total absolute doses. Having all 
these data allows extracting doses calculated by the Eclipse TPS at any point or in any plane in the 
phantom and comparison to the doses measured by radiochromic films and TLDs. 
 
Figure 2.14 Eclipse Export Wizard Settings Window 
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The analysis of the data was performed in a Computational Environment for Radiotherapy 
Research (CERR) v.3.3 implemented within the numerical computing environment of MATLAB 
(R2008b) (MathWorks®, Natick, MA). CERR allows conversion of the information from different 
TPSs into a common file format and provides powerful tools for development and assessment of 
multiple treatment planning concepts [27]. 
Every exported plan was converted and saved into a single MATLAB file format containing 
information about CT scans, outlined structures, and calculated 3D dose distributions. Single point, 
volume doses, as well as 2D doses distributions in any plane could be easily extracted from this file 
and analyzed. 
2.5.2 TLD Data 
As was mentioned in (chapter 2.3.1) four TLD regions of interest were created for every plan. 
The location of these ROIs was selected to be the same as geometrical locations of physical TLD 
capsules placed in heart, spine, and tumor inserts. The Eclipse TPS calculated the mean volume dose 
to each outlined ROI. These values were used to determine one of this work’s objectives: measured-
to-predicted TLD ratios. 
2.5.3 Film Data Processing 
The 2D film data analysis was performed using an in-house developed code RPCFILM 
(Figure 2.15). To streamline the workflow and to be able to access the treatment planning system 
data this code functioned within the same computational environment of MATLAB as CERR. This 
integration allows RPCFILM code to register film data to the data calculated by Eclipse TPS.  
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Figure 2.15 RPCFILM With Loaded And Registered Axial Film Image File 
 
Before this code could be used for film analysis it required some additional data. To correct 
the information obtained from the films, RPCFILM uses doses measured by the TLDs, and therefore 
it is important to have the TLD dose calculations done prior to analysis. Since every phantom used 
by the RPC is unique, a full phantom profile had to be created. This profile contains the coordinates 
of all film perforations and was done using following method. A clear template that copies the shape 
of films was placed inside the phantom in the same way the actual film would go and insert was fully 
assembled. A pinprick was used to puncture the template the same way as if a film was used.  The 
insert was opened and the template was removed. Distances from the center of coordinates (center of 
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the tumor) to the holes in the template were measured. Positions of the TLD capsules were also 
marked on each film. 3D coordinates were associated with each film in such way that the axial film 
only uses (X,Y) pair, coronal (X,Z) pair, and sagittal (Y,Z) pair. The profile for the L23 RPC Lung 
phantom had the following coordinates (Table 2.4). 
Table 2.4 L23 RPC Lung Phantom Profile Data 
  
X, mm Y, mm Z, mm 
Film 
Axial 
Left anterior -39 26 0 
Left posterior -39 -30.5 0 
Right anterior 30.5 25 0 
Coronal 
Superior left -42.5 0 50 
Superior right 41 0 53 
Inferior left -39.5 0 -52 
Inferior right 42.5 0 -49.5 
Sagittal 
Superior posterior 0 -45 40.5 
Superior anterior 0 41.5 37.5 
Inferior posterior 0 -45 -38.5 
Inferior anterior 0 44.5 -40.5 
  TLD 
Axial Superior/Inferior 3.5 -3.5 0 
Coronal 
Superior 4 0 6 
Inferior 4 0 -6 
Sagittal 
Superior 0 -3.5 6 
Inferior 0 -3.5 -6 
 
Another file was created that contained information on regions of interest for the 2D gamma 
analysis. In this work a single gamma index region of interest of PTV + 2cm was chosen. The last 
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piece of data required for the film analysis was the dose response curve (chapter 2.5.1.1). The 
polynomial fit coefficients for the dose response curve were loaded into the third configuration file. 
After the launch of the RPCFILM in MATLAB the following step-by-step procedure was 
used to prepare film data for analysis. 
1. A file containing the film image in .fit format (chapter 2.4.1.2) was loaded into 
memory. 
2. From the drop-down menu the correct phantom profile containing registration 
information was selected 
3. Since every axial, coronal, and sagittal film was analyzed separately, an orthogonal 
plane that corresponded to the loaded image file was selected. 
4. Depending on the film plane selected, a set of registration points in a specific order 
was loaded from the phantom profile file. Each point was assigned a numeric 
coordinate value by marking corresponding pricks (chapter 2.2.1) on the film image. 
To verify the accuracy of the 2D registration a root mean square (RMS) error value 
was calculated after “Register” button was pressed. 
5. After the successful 2D registration of the film the proper Dose Response Curve 
profile was selected. After the DRC was loaded, the program calculated the dose at 
the TLD position by converting optical densities of the film using the coordinates 
from the phantom profile. The axial films had one value assigned to TLD dose 
corresponding to the average of both superior and inferior TLDs, while coronal and 
sagittal films had separate values for each TLD. Once the TLD position dose was 
obtained from the film OD, a correction coefficient was calculated by dividing the 
film dose by that obtained for the corresponding TLD capsule (chapter 2.5.2.2). 
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6. After all corrections were applied, the final step was registering the film to a 3D 
volume dose dataset. In this step, after pressing “Register 3D” RPCFILM launched 
the CERR environment and asks the user to load the corresponding plan (Figure 
2.16). A total of five points were used in the 3D registration: superior and inferior 
edges of the tumor, anterior edge of the lung insert, center of the tumor along the 
central axis, and the final point was registering the medial edge of the tumor in the 
central axial plane. After the successful registration, CERR will produce a 2D dose 
distribution that corresponds to the same plane as the film being analyzed. Similar to 
2D registration, after the 3D registration has been completed the RPCFILM calculates 
3D RMS Error. 
 
Figure 2.16 CERR Window With Loaded Plan 
 
7. Following the last step, the film image with matching registration data, OD-to-Dose 
conversion, TLD corrections, and 2D dose distribution extracted from CERR were 
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saved into a single MATLAB file. This file provides a convenient way of presenting 
all the necessary information for further analysis.     
2.5.4 Film Data Analysis 
 After the film data processing was completed and saved into file a 2D gamma analysis was 
performed. This was done using RPCFILM code - the same software code that was used in film data 
processing. Gamma analysis requires input of two values for dose-to-agreement (in %) and distance-
to-agreement (in mm) (Figure 2.17).  
 
 
 
 
 
 
 
 
 
Figure 2.17 2D Gamma Index Using Dose And Distance To Agreement Criteria 
 
The actual gamma index  (  ⃗⃗  ) is calculated as a minimum value of  (  ⃗⃗     ⃗⃗⃗  ) according to the 
following formulas: 
 (  ⃗⃗  )     
  
 (  ⃗⃗     ⃗⃗⃗  ) 
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Gamma ≤1 
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Measured profile 
Calculated profile 
Closest point passes (γ<1) 
Closest point fails (γ>1) 
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And 
 (  ⃗⃗     ⃗⃗⃗  )  √
|  ⃗⃗  ⃗   ⃗⃗  ⃗| 
   
 
|  (  ⃗⃗  ⃗)   (  ⃗⃗  ⃗)| 
   
, 
Where 
   ⃗⃗         ⃗⃗⃗   are the evaluated and reference vector point positions,   (  ⃗⃗⃗  )     (  ⃗⃗  ) 
are the evaluated and reference doses, respectively and Δd and ΔD are the distance-to-agreement 
and dose difference criteria, respectively [28].  
Two sets of criteria, ±5%/3mm and ±8%/3mm, were used in this work. RPCFILM code 
calculates a passing rate of pixels (gamma index <1) around unity using these criteria. A first set of 
criteria of ±5%/3mm was stated in the hypothesis (chapter 1.4). The reason for the second set was 
that for the heterogeneity-corrected dose in anthropomorphic thorax phantoms the RPC uses gamma 
index around ratio of 0.97 instead of 1. This was done based on the RPC data [29, 30] that 
demonstrated that the average measured-to-calculated dose ratio in the target was 0.97 (0.92-0.99 
range). In order to be able to perform a comparison of the plans created in this study to the standards 
used by the RPC, gamma index analysis using ±8%/3mm criteria was also performed on all plans. 
 After the appropriate criteria were entered, the correct region of interest was selected. As 
was pointed out in chapter 2.6.3, all films were analyzed using single ROI equal to PTV+2cm. Axial 
PTV+2 was equal to 8 cm (-4…+4 cm) in the axial plane, while coronal and sagittal films had 
PTV+2cm ROIs equal to 11 cm (-5.5…+5.5 cm) in the superior-inferior and 8 cm in the lateral and 
anterior-posterior directions. Selecting ROI for gamma analysis opens a new window showing dose 
distributions limited to this region. The option to mask some areas of this image was used to exclude 
from gamma index analysis any pixels that were part of pinprick marks that were used in film 
registration, coronal and sagittal film slits that were cut in order to load the axial film (chapter 2.2.1), 
as well as any dust particles, scratches, or other damage that could have happened prior to scanning 
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in the process of film handling. After the masking was complete, RPCFILM code calculated and 
displayed the gamma index map and a number of pixels (in %) that passed the specified criteria. This 
map has two options of displaying the results. The color-coded (standard) option displays pixel map 
using color spectrum from dark blue (value of 0 having the best agreement) to dark red (gamma 
index greater than 2 having the worst agreement) with color green being 1. Values greater than 2 are 
truncated to 2. The second option, binary, presents passing pixels (gamma index <1) as white while 
failing pixels (gamma index >1) as dark grey. Binary mode doesn’t show how close each pixel is to 
passing or failing while first option could provide some additional information about spatial dose 
distribution or profile shapes. The color-coded gamma index maps of every film were saved into a 
file and the passing rates were analyzed and plotted using Microsoft ® Excel (Redmond, WA) 
software. 
 The second part of film analysis consisted of extracting dose profiles. In this step, a total of 
two sets of two dose profiles each were pulled from every film data file. A single set represented a 
measured and calculated dose profiles in one of the directions depending on the film being analyzed. 
Axial film produced two sets in X (right-left) and Y (anterior-posterior) directions, coronal resulted 
in X and Z (superior-inferior) profiles, and sagittal in Y and Z directions. These profiles were 
imported into an Excel spreadsheet. A 10-point Simple Moving Average smoothing was applied to 
every measured profile that was plotted along with calculated dose profile and the PTV boundaries. 
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Chapter 3 Results and Discussion 
  
3.1 Dose Response Curve  
The Dose Response Curve was calculated following the procedure described in chapter 
2.5.1.1.  As was mentioned earlier, in order to relate an unknown dose to a known film optical 
density the relationship between a known dose and known OD had to be established. In order to have 
a reliable dose-OD relationship a range of doses for the dose response films had to be irradiated that 
covered both lower and higher limits of expected doses. Eight different doses in fixed geometry were 
delivered to films resulting in 8 distinct levels of optical density. Table 3.1 shows the delivered doses 
and their corresponding ODs for the EBT2 (Lot # A06271103) radiochromic film. The same lot was 
used throughout the whole study for all phantom irradiations. 
Table 3.1 Dose Response Film Data Points 
MU Dose, Gy OD 
50 0.548 0.137 
150 1.643 0.306 
250 2.738 0.416 
350 3.833 0.497 
550 6.023 0.618 
750 8.213 0.702 
950 10.403 0.756 
1150 12.593 0.811 
 
 The function, relating Dose to OD, was plotted (Figure 3.1) and a third order polynomial fit 
based on these data points resulted in the following equation: 
D = 28.431∙OD3 – 11.77∙OD2 + 6.2869∙OD 
Where 
D – Dose received by film; 
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OD – Film optical density. 
Since during the film scanning step (chapter 2.5.1.2) optical densities of background 
(flatfield) was subtracted from the optical densities of dose response and phantom films this 
polynomial regression was calculated with the X and Y intercept at 0. This means that 0 OD will 
equate to 0 Gy. To verify “goodness of fit”, R2, coefficient was determined. It shows how well a 
function fits the set of observations with 1 being an ideal fit and 0 being the worst match. R
2
 was 
calculated to be 0.999 demonstrating that obtained equation describes experimental data very well.  
 
Figure 3.1 Plot Of Dose Response Curve And Its Polynomial Fit 
 
3.2 MD Anderson Cancer Center Treatment Plans 
Both 6 MV and 18 MV plans were developed in Research Eclipse treatment planning system. 
AAA v.8.9.08 heterogeneity correction was applied for volume dose calculations in both plans. Plan 
dose prescription and limits were discussed in chapter 2.3.1. Each plan was normalized so that 6 Gy 
in single fraction was to be delivered to at least 95% of the PTV volume using a total of nine fields at 
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25⁰, 60⁰, 115⁰, 150⁰, 180⁰, 220⁰, 260⁰, 285⁰, and 345⁰ (Figure 2.5). In each case the tumor coverage 
was achieved by using only beams of specified energy, such as the only photon energy allowed in 
3D SBRT 6 MV plan was 6 MV x-rays etc. Keeping all other variables(isocenter, fields setup, dose 
rate, and collimator jaws and MLC positions) constant and only changing the energy of the treatment 
beam, allows relating any changes in the final dose distribution to the effectiveness of the dose 
calculation and heterogeneity correction of the anisotropic analytical algorithm itself.  
To minimize the effect of fading, all TLD capsules were read 14 days post-irradiation. TLD 
readings (in charge per unit mass [μC/mg]) were converted into dose (in cGy) as described in chapter 
2.5.2.2. Each plan was delivered three times to the phantom, resulting in two target TLDs per 
irradiation for a total of 36 target doses. Corresponding doses were extracted from the treatment 
planning system and a measured-to-predicted ratio was calculated. Each TLD dose was corrected for 
the variations in linear accelerator daily output. The RPC currently uses passing criteria of 
0.97±0.05. In this work, if this ratio was within ±5% of the absolute dose the TLD was passing 
otherwise it was considered to be failing the point dose test. 
3.2.1  MD Anderson: 3D SBRT 6 MV Plan 
3.2.1.1 Plan Details  
 After all required structures were contoured a number of beam placements were tested to 
find an optimal configuration that met the plan objectives. Figure 3.2 shows phantom axial plane 
with final beam placement, while Figure 3.3 shows the colorwash dose distribution on the same axial 
slice. Colorwash display maps out dose intensity from the lowest (blue) to the highest (red). The 
dose range (window) was selected to display the doses between 15% of the prescribed dose to 
maximum (in this case 120.8%). The plan’s calculated dose was in a good agreement with RTOG 
requirements for Conformality Index, normal tissue dose spillage and dose restrictions (chapter 
2.3.1). 
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Figure 3.2 3D SBRT 6 MV Plan - Axial Plane Beam Placement 
 
 
Figure 3.3 3D SBRT 6 MV Plan - Axial Plane Colorwash Dose Distribution 
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Figure 3.4 represents a 3-plane view of the tumor and the calculated isodose map. Calculated 
dose takes advantage of AAA heterogeneity correction and demonstrates an excellent conformality 
in all three planes. A magnified view of the same axial plane is shown in Figure 3.5. 
 
Figure 3.4 3-Plane View Of The Tumor And The Isodose Map 
 
 
Figure 3.5 A Magnified Axial Plane View Of The Tumor And The Isodose Map 
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A Dose Volume Histogram (DVH) represents a cumulative relationship between the 
absolute (or relative) dose and the volume of the region of interest that receives that dose. It can be 
seen from Figure 3.6 that non-tumor tissues (lung, heart, and spine) received radiation dose well 
below the established RTOG and RPC limits for normal tissues. At the same time, the tumor 
coverage complied with the specified prescription described in Treatment Planning section. 
 
 
Figure 3.6 3D SBRT plan – Dose Volume Histogram 
3.2.1.2 Target TLD Results  
Table 3.2 shows superior and inferior target TLD data corrected for daily output and Figure 
3.7 displays a histogram of the measured-to-predicted dose ratios for target TLDs. The averages have 
error bars representing the 95% confidence interval (CI) plotted as well. 
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Table 3.2 Target TLD Results. 6 MV, MD Anderson 
Plan: 6 MV, MD Anderson, Clinac 2100CD 
Phantom 
Irradiation 
№ 
TLD Dose, Gy 
Daily 
Output 
Correction 
Corrected TLD Dose, 
Gy 
Eclipse Calculated 
Dose, Gy 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
1 6.9899 7.0287 
1.015 
6.8866 6.9249 
7.161 7.167 2 7.1064 7.0618 7.0014 6.9575 
3 7.0897 7.0762 6.9849 6.9716 
Average 6.9576 6.9513 7.164 
Measured/Predicted Ratio 0.972 0.970 0.971 
 
 
Figure 3.7 Measured-To-Predicted Dose Ratios Of Target TLDs For 6 MV Plan (MDA CC) 
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3.2.1.3 2D Gamma Index Analysis Results  
As was mention in Film Data Analysis (chapter 2.6.4) section, two sets of criteria, 
±5%/3mm and ±8%/3mm, were used in this work. This resulted in two sets of gamma index maps 
per plane for a total of 18 maps per plan. Figures 3.8-3.10 show examples of the 2D gamma index 
results for the first irradiation of the phantom at MD Anderson Cancer Center using a 6 MV 3D 
SBRT plan and ±5%/3mm gamma criteria. Gamma analysis results using ±8%/3mm criteria, as well 
as results for other irradiations are shown in the Appendix.  
Table 3.3 summarizes the 2D gamma index results for all three irradiations (using 6 MV 
plan) of the RPC phantom at MD Anderson.  
 
Figure 3.8 2D Gamma Index Results: ±5%/3mm, Axial Plane For 6 MV Plan 
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Figure 3.9 2D Gamma Index Results: ±5%/3mm, Coronal Plane For 6 MV Plan 
 
 
Figure 3.10 2D Gamma Index Results: ±5%/3mm, Sagittal Plane For 6 MV Plan 
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Table 3.3 6 MV Plan 2D Gamma Index Results, MD Anderson 
Plan: 6 MV, MD Anderson, Clinac 2100CD 
Phantom Irrad.№ 
Gamma Index 
Analysis 
Criteria 
Orthogonal Plane Passing Rate, % Average 
3-planes, 
% 
Standard 
Deviation 
3-planes Axial Coronal Sagittal 
1 
±5%/3mm 96.3% 97.5% 96.3% 96.7% 0.70% 
±8%/3mm 99.7% 99.9% 99.9% 99.8% 0.15% 
2 
±5%/3mm 96.6% 96.0% 94.4% 95.7% 1.13% 
±8%/3mm 99.6% 99.4% 99.9% 99.7% 0.26% 
3 
±5%/3mm 95.6% 98.7% 95.1% 96.5% 1.98% 
±8%/3mm 99.7% 99.9% 99.9% 99.8% 0.13% 
Ave.Passing Rate 
– All Irradiations, 
% 
±5%/3mm 96.2% 97.4% 95.3% 96.3% 
 
±8%/3mm 99.7% 99.8% 99.9% 99.8% 
Std Deviation – 
All Irradiations, 
% 
±5%/3mm 0.53% 1.36% 0.98% 0.55% 
±8%/3mm 0.03% 0.27% 0.03% 0.09% 
 
A plot of the data in Table 3.3 is presented in Figures 3.11-3.12. Error bars represent the 95% CI. 
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Figure 3.11 2D Gamma Index Results Using ±5%/3mm Criteria For 6 MV Plan 
 
Figure 3.12 2D Gamma Index Results Using ±8%/3mm Criteria For 6 MV Plan 
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3.2.1.4 Dose Profiles Results 
Two dose profiles per plane where acquired (chapter 2.6.4) and plotted using Excel.  The 
example of Right-Left, Anterior-Posterior, and Superior-Inferior measured (film) and calculated 
(TPS) profiles for the first irradiation of the phantom in MD Anderson Cancer Center using 6 MV 
3D SBRT plan are shown in Figures 3.13-3.15. Plane specific profiles for other irradiations and their 
corresponding TLD doses are presented in the Appendix. 
 
Figure 3.13 Right-Left Profiles In Axial And Coronal Planes Compared To The Calculated Dose Profiles 
For 6 MV Plan 
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Figure 3.14 Anterior-Posterior Profiles In Axial And Sagittal Planes Compared To The Calculated Dose 
Profiles For 6 MV Plan 
 
Figure 3.15 Superior-Inferior Profiles In Coronal And Sagittal Planes Compared To The Calculated 
Dose Profiles For 6 MV Plan 
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3.2.2 MD Anderson: 3D SBRT 18 MV Plan 
3.2.2.1 Plan Details  
 Figure 3.16 shows phantom axial plane with final beam placement, while Figure 3.17 shows 
the colorwash dose distribution on the same axial slice. The dose range (window) was selected to 
display the doses between 15% of the prescribed dose to maximum (in this case 128.5%). Calculated 
dose was in a good agreement with RTOG requirements for Conformality Index, normal tissue dose 
spillage and dose restrictions (chapter 2.3.1). 
 
 
Figure 3.16 3D SBRT 18 MV Plan - Axial Plane Beam Placement 
 
54 
 
 
Figure 3.17 3D SBRT 18 MV Plan - Axial Plane Colorwash Dose Distribution 
Figure 3.18 shows a 3-plane view of the tumor and the calculated isodose map. Calculated 
dose takes advantage of AAA heterogeneity correction and demonstrates good conformality in all 
three planes. A magnified view of the same axial plane is shown in Figure 3.19. 
 
Figure 3.18 3-Plane View Of The Tumor And The Isodose Map 
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Figure 3.19 A Magnified Axial Plane View Of The Tumor And The Isodose Map 
Figure 3.20 shows a Dose Volume Histogram for the calculated dose distribution. As with 
6MV plan the radiation doses to non-tumor tissues such as lung, heart, and spine are substantially 
lower than the established RTOG and RPC limits while the tumor was covered according to the 
prescribed dose.  
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Figure 3.20 3D SBRT plan – Dose Volume Histogram 
3.2.2.2 Target TLD Results  
Table 3.4 shows superior and inferior target TLD data corrected for daily output and Figure 
3.21 displays measured-to-predicted dose ratios for target TLDs. The averages have error bars 
representing the 95% confidence interval (CI) plotted as well. 
Table 3.4 Target TLD Results. 18 MV, MD Anderson 
Plan: 18 MV, MD Anderson, Clinac 21EX 
Phantom 
Irradiation 
№ 
TLD Dose, Gy 
Daily 
Output 
Correction 
Corrected TLD Dose, 
Gy 
Eclipse Calculated 
Dose, Gy 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
1 7.8470 7.7038 
0.997 
7.8706 7.7270 
7.609 7.627 2 7.8012 7.7931 7.8246 7.8166 
3 7.7922 7.7750 7.8156 7.7984 
Average 7.8370 7.7807 7.618 
Measured/Predicted Ratio 1.03 1.02 1.025 
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Figure 3.21 Measured-To-Predicted Dose Ratios Of Target TLDs For 18 MV Plan (MDA CC) 
 
3.2.2.3 2D Gamma Index Analysis Results  
Figures 3.22-3.24 show examples of 2D gamma index results for one of the irradiations of 
the phantom in MD Anderson Cancer Center using 18 MV 3D SBRT plan and ±5%/3mm criteria. 
Gamma analysis results using ±8%/3mm criteria, as well as results for other irradiations are 
presented in the Appendix.  
Table 3.5 summarizes 2D gamma index results for all three irradiations (using the 18 MV 
plan) of the RPC phantom at MD Anderson.  
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Figure 3.22 2D Gamma Index Results: ±5%/3mm, Axial Plane For 18 MV Plan 
 
 
Figure 3.23 2D Gamma Index Results: ±5%/3mm, Coronal Plane For 18 MV Plan 
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Figure 3.24 2D Gamma Index Results: ±5%/3mm, Sagittal Plane For 18 MV Plan 
  
Table 3.5 18 MV Plan 2D Gamma Index Results, MD Anderson 
Plan: 18 MV, MD Anderson, Clinac 21EX 
Phantom Irrad.№ 
Gamma Index 
Analysis 
Criteria 
Orthogonal Plane Passing Rate, % Average 
3-planes, 
% 
Standard 
Deviation 
3-planes Axial Coronal Sagittal 
1 
±5%/3mm 99.1% 86.9% 90.6% 92.2% 6.24% 
±8%/3mm 100.0% 99.9% 100.0% 100.0% 0.02% 
2 
±5%/3mm 94.8% 88.1% 90.9% 91.3% 3.39% 
±8%/3mm 99.7% 99.6% 100.0% 99.8% 0.20% 
3 
±5%/3mm 98.3% 88.7% 92.7% 93.2% 4.80% 
±8%/3mm 99.8% 99.9% 100.0% 99.9% 0.08% 
Ave.Passing Rate 
– All Irradiations, 
% 
±5%/3mm 97.4% 87.9% 91.4% 92.2% 
 
±8%/3mm 99.8% 99.8% 100.0% 99.9% 
Std Deviation – 
All Irradiations, 
% 
±5%/3mm 2.24% 0.93% 1.15% 0.98% 
±8%/3mm 0.14% 0.19% 0.02% 0.10% 
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A plot of the data in the Table 3.5 is presented in Figures 3.25-3.26. Error bars represent the 95% CI. 
 
Figure 3.25 2D Gamma Index Results Using ±5%/3mm Criteria For 18 MV Plan 
 
Figure 3.26 2D Gamma Index Results Using ±8%/3mm Criteria For 18 MV Plan 
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3.2.2.4 Dose Profiles Results 
The example of Right-Left, Anterior-Posterior, and Superior-Inferior measured (film) and 
calculated (TPS) profiles for the first irradiation of the phantom in MD Anderson using the 18 MV 
3D SBRT plan are shown in Figures 3.27-3.29. Plane specific profiles for other irradiations and their 
corresponding TLD doses are presented in the Appendix.  
 
Figure 3.27 Right-Left Profiles In Axial And Coronal Planes Compared To The Calculated Dose Profiles 
For 18 MV Plan 
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Figure 3.28 Anterior-Posterior profiles in axial and sagittal planes compared to the calculated dose 
profiles for 18 MV plan 
 
Figure 3.29 Superior-Inferior Profiles In Coronal And Sagittal Planes Compared To The Calculated 
Dose Profiles For 18 MV Plan 
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3.3 University of Alabama at Birmingham Medical Center Treatment Plans 
The 6 MV treatment plan designed with the research Eclipse treatment planning system at MD 
Anderson Cancer Center was imported into the University of Alabama Medical Center clinical 
Eclipse TPS (chapter 2.3.1). The same version of AAA (v.8.9.08) heterogeneity correction was used 
to recalculate the dose using UAB beam models. Field placements, target coverage, and critical 
organ dose limits were identical for all plans (chapter 2.3.1). From this plan 15 MV, 6 MV FFF, and 
10MV FFF plans were created by modifying each field’s beam energy to each plan’s respective 
values while keeping other parameters unchanged.  
3.3.1 UAB: 3D SBRT 6 MV Plan 
3.3.1.1 Plan Details  
Figure 3.30 represents a 3-plane view of the tumor and the calculated isodose map. 
Calculated dose takes advantage of AAA heterogeneity correction and demonstrates an excellent 
conformality in all three planes. Figure 3.31 shows a magnified view of the same axial plane.  
Figure 3.32 shows a Dose Volume Histogram for the calculated dose distribution. As with 
previously discussed treatment plans the radiation doses to non-tumor tissues such as lung, heart, and 
spine were substantially lower than the established RTOG and RPC limits while the tumor was 
covered according to the prescribed dose. 
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Figure 3.30 3-Plane View Of The Tumor And The Isodose Map 
 
 
Figure 3.31 A Magnified Axial Plane View Of The Tumor And The Isodose Map 
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Figure 3.32 6MV 3D SBRT Plan – Dose Volume Histogram 
3.3.1.2 Target TLD Results  
Table 3.6 shows superior and inferior target TLD data corrected for daily output and Figure 
3.33 displays measured-to-predicted dose ratios for target TLDs. The averages have corresponding 
error bars representing 95% confidence intervals (CI) plotted as well.  
Table 3.6 Target TLD Results. 6 MV, UAB 
Plan: 6 MV, UAB, TrueBeam STx 
Phantom 
Irradiation 
№ 
TLD Dose, Gy 
Daily 
Output 
Correction 
Corrected TLD Dose, 
Gy 
Eclipse Calculated 
Dose, Gy 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
1 7.3475 7.2994 
0.988 
7.4366 7.3879 
7.744 7.749 2 7.2584 7.3451 7.3465 7.4342 
3 7.3296 7.3494 7.4185 7.4385 
Average 7.4005 7.4202 7.747 
Measured/Predicted Ratio 0.956 0.958 0.957 
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Figure 3.33 Measured-to-predicted dose ratios of target TLDs for 6 MV plan (UAB MC) 
3.3.1.3 2D Gamma Index Analysis Results  
Figures 3.34-3.36 show examples of 2D gamma index results for the first irradiation of the 
phantom in UAB Medical Center using 6 MV 3D SBRT plan and a ±5%/3mm criteria. Gamma 
analysis results using a ±8%/3mm criteria, as well as results for other irradiations are presented in the 
Appendix.  
Table 3.7 summarizes the 2D gamma index results for all three irradiations (using the 6 MV 
plan) of the RPC phantom at University of Alabama at Birmingham.  
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Figure 3.34 2D Gamma Index Results: ±5%/3mm, Axial Plane For 6 MV Plan 
 
 
Figure 3.35 2D Gamma Index Results: ±5%/3mm, Coronal Plane For 6 MV Plan 
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Figure 3.36 2D Gamma Index Results: ±5%/3mm, Sagittal Plane For 6 MV Plan  
Table 3.7 6 MV Plan 2D Gamma Index Results, UAB 
Plan: 6 MV, UAB, TrueBeam STx 
Phantom Irrad.№ 
Gamma Index 
Analysis 
Criteria 
Orthogonal Plane Passing Rate, % Average 
3-planes, 
% 
Standard 
Deviation 
3-planes Axial Coronal Sagittal 
1 
±5%/3mm 97.0% 97.4% 94.6% 96.3% 1.50% 
±8%/3mm 99.9% 99.7% 99.1% 99.6% 0.40% 
2 
±5%/3mm 95.1% 97.0% 93.2% 95.1% 1.90% 
±8%/3mm 99.1% 99.8% 98.7% 99.2% 0.59% 
3 
±5%/3mm 97.7% 97.3% 90.5% 95.2% 4.03% 
±8%/3mm 99.7% 99.6% 98.6% 99.3% 0.65% 
Ave.Passing Rate 
– All Irradiations, 
% 
±5%/3mm 96.6% 97.2% 92.8% 95.6% 
 
±8%/3mm 99.6% 99.7% 98.8% 99.4% 
Std Deviation – 
All Irradiations, 
% 
±5%/3mm 1.35% 0.20% 2.07% 0.68% 
±8%/3mm 0.41% 0.11% 0.30% 0.19% 
 
A plot of the data in the Table 3.7 is presented in Figures 3.37-3.38. Error bars represent the 95% CI. 
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Figure 3.37 2D Gamma Index Results Using ±5%/3mm Criteria For 6 MV Plan 
 
Figure 3.38 2D Gamma Index Results Using ±8%/3mm Criteria For 6 MV Plan 
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3.3.1.4 Dose Profiles Results 
The example of Right-Left, Anterior-Posterior, and Superior-Inferior measured (film) and 
calculated (TPS) profiles for the first irradiation of the phantom in UAB Medical Center using the 6 
MV 3D SBRT plan are shown in Figures 3.39-3.41. Plane specific profiles for other irradiations and 
their corresponding TLD doses are presented in the Appendix. 
 
Figure 3.39 Right-Left Profiles In Axial And Coronal Planes Compared To The Calculated Dose Profiles 
For 6 MV Plan 
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Figure 3.40 Anterior-Posterior Profiles In Axial And Sagittal Planes Compared To The Calculated Dose 
Profiles For 6 MV Plan 
 
Figure 3.41 Superior-Inferior Profiles In Coronal And Sagittal Planes Compared To The Calculated 
Dose Profiles For 6 MV Plan 
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3.3.2 UAB: 3D SBRT 15 MV Plan  
3.3.2.1 Plan Details  
Figure 3.42 represents a 3-plane view of the tumor and the calculated isodose map. 
Calculated dose demonstrates a good conformality in all three planes. A magnified view of the same 
axial plane is shown in Figure 3.43. 
 
Figure 3.42 3-Plane View Of The Tumor And The Isodose Map 
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Figure 3.43 A Magnified Axial Plane View Of The Tumor And The Isodose Map 
Figure 3.44 shows a Dose Volume Histogram for the calculated dose distribution. As with 
previously discussed treatment plans the radiation doses to non-tumor tissues such as lung, heart, and 
spine were substantially lower than the established RTOG and RPC limits while the tumor was 
covered according to the prescribed dose. 
 
Figure 3.44 15MV 3D SBRT Plan – Dose Volume Histogram 
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3.3.2.2 Target TLD Results  
Table 3.8 shows superior and inferior target TLD data corrected for daily output and Figure 
3.45 displays measured-to-predicted dose ratios for target TLDs. The averages have error bars 
representing the 95% confidence interval (CI) plotted as well.  
Table 3.8 Target TLD Results. 15 MV, UAB 
Plan: 15 MV, UAB, TrueBeam STx 
Phantom 
Irradiation 
№ 
TLD Dose, Gy 
Daily 
Output 
Correction 
Corrected TLD Dose, 
Gy 
Eclipse Calculated 
Dose, Gy 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
1 7.9980 8.0035 
0.987 
8.1031 8.1087 
8.143 8.155 2 8.0069 8.0645 8.1122 8.1704 
3 7.9545 7.9686 8.0590 8.0733 
Average 8.0914 8.1175 8.149 
Measured/Predicted Ratio 0.994 0.995 0.995 
 
Figure 3.45 Measured-To-Predicted Dose Ratios Of Target TLDs For 15 MV Plan (UAB MC) 
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3.3.2.3 2D Gamma Index Analysis Results  
Figures 3.46-3.48 show examples of 2D gamma index results for one of the irradiations of 
the phantom in UAB Medical Center using 15 MV 3D SBRT plan and ±5%/3mm criteria. Gamma 
analysis results using ±8%/3mm criteria, and results for other irradiations are presented in the 
Appendix.  
 
Figure 3.46 2D Gamma Index Results: ±5%/3mm, Axial Plane For 15 MV Plan 
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Figure 3.472D Gamma Index Results: ±5%/3mm, Coronal Plane For 15 MV Plan 
 
 
Figure 3.48 2D Gamma Index Results: ±5%/3mm, Sagittal Plane For 15 MV Plan 
 
 
77 
 
Table 3.9 summarizes 2D gamma index results for all three irradiations (using the 15 MV plan) of 
the RPC phantom at University of Alabama at Birmingham.  
 
Table 3.9 15 MV Plan 2D Gamma Index Results, UAB 
Plan: 15 MV, UAB, TrueBeam STx 
Phantom Irrad.№ 
Gamma Index 
Analysis 
Criteria 
Orthogonal Plane Passing Rate, % Average 
3-planes, 
% 
Standard 
Deviation 
3-planes Axial Coronal Sagittal 
1 
±5%/3mm 100.0% 96.9% 93.0% 96.0% 2.60% 
±8%/3mm 99.9% 99.9% 99.8% 99.9% 0.04% 
2 
±5%/3mm 99.7% 97.4% 96.8% 98.0% 1.56% 
±8%/3mm 100.0% 99.9% 99.8% 99.9% 0.09% 
3 
±5%/3mm 98.9% 98.6% 97.2% 98.2% 0.93% 
±8%/3mm 100.0% 100.0% 100.0% 100.0% 0.01% 
Ave.Passing Rate 
– All Irradiations, 
% 
±5%/3mm 98.9% 97.6% 95.7% 97.4% 
 
±8%/3mm 99.9% 99.9% 99.9% 99.9% 
Std Deviation – 
All Irradiations, 
% 
±5%/3mm 0.88% 0.91% 2.27% 1.23% 
±8%/3mm 0.03% 0.03% 0.08% 0.04% 
 
A plot of the data in the Table 3.9 is presented in Figures 3.49-3.50. Error bars represent the 95% CI. 
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Figure 3.49 2D Gamma Index Results Using ±5%/3mm Criteria For 15 MV Plan 
 
 
Figure 3.50 2D Gamma Index Results Using ±8%/3mm Criteria For 15 MV Plan 
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3.3.2.4 Dose Profiles Results 
The example of Right-Left, Anterior-Posterior, and Superior-Inferior measured (film) and 
calculated (TPS) profiles for the first irradiation of the phantom in UAB Medical Center using the 15 
MV 3D SBRT plan are shown in Figures 3.51-3.53. Plane specific profiles for other irradiations and 
their corresponding TLD doses are presented in the Appendix. 
 
Figure 3.51 Right-Left profiles in axial and coronal planes compared to the calculated dose profiles for 
15 MV plan 
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Figure 3.52 Anterior-Posterior profiles in axial and sagittal planes compared to the calculated dose 
profiles for 15 MV plan 
 
Figure 3.53 Superior-Inferior profiles in coronal and sagittal planes compared to the calculated dose 
profiles for 15 MV plan 
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3.3.3 UAB: 3D SBRT 6 MV FFF Plan  
3.3.3.1 Plan Details  
Figure 3.54 represents a 3-plane view of the tumor and the calculated isodose map. 
Calculated dose demonstrates a good conformality in all three planes. A magnified view of the same 
axial plane is shown in Figure 3.55. 
 
Figure 3.54 3-Plane View Of The Tumor And The Isodose Map 
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Figure 3.55 A Magnified Axial Plane View Of The Tumor And The Isodose Map 
Figure 3.56 shows a Dose Volume Histogram for the calculated dose distribution. As with 
previously discussed treatment plans the radiation doses to non-tumor tissues such as lung, heart, and 
spine were substantially lower than the established RTOG and RPC limits while the tumor was 
covered according to the prescribed dose. 
 
Figure 3.56 6MV FFF 3D SBRT Plan – Dose Volume Histogram 
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3.3.3.2 Target TLD Results  
Table 3.10 shows superior and inferior target TLD data corrected for daily output and Figure 
3.57 displays measured-to-predicted dose ratios for target TLDs. The averages have error bars 
representing the 95% confidence interval (CI) plotted as well.  
Table 3.10 Target TLD Results. 6 MV FFF, UAB 
Plan: 6 MV FFF, UAB, TrueBeam STx 
Phantom 
Irradiation 
№ 
TLD Dose, Gy 
Daily 
Output 
Correction 
Corrected TLD Dose, 
Gy 
Eclipse Calculated 
Dose, Gy 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
1 7.4641 7.5838 
0.998 
7.4796 7.5996 
7.874 7.866 2 7.5038 7.5646 7.5194 7.5803 
3 7.4653 7.5203 7.4809 7.5360 
Average 7.4933 7.5720 7.870 
Measured/Predicted Ratio 0.952 0.963 0.957 
 
Figure 3.57 Measured-To-Predicted Dose Ratios Of Target TLDs For 6 MV FFF Plan (UAB MC) 
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3.3.3.3 2D Gamma Index Analysis Results  
Figures 3.58-3.60 show examples of 2D gamma index results for one of the irradiations of 
the phantom in UAB Medical Center using the 6 MV FFF 3D SBRT plan and ±5%/3mm criteria. 
Gamma analysis results using ±8%/3mm criteria, as well as results for other irradiations are 
presented in the Appendix.  
Table 3.11 summarizes 2D gamma index results for all three irradiations (using 6 MV FFF 
plan) of the RPC phantom at University of Alabama at Birmingham.  
 
 
Figure 3.58 2D Gamma Index Results: ±5%/3mm, Axial Plane For 6 MV FFF Plan 
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Figure 3.59  2D Gamma Index Results: ±5%/3mm, Coronal Plane For 6 MV FFF Plan 
 
 
Figure 3.60  2D Gamma Index Results: ±5%/3mm, Sagittal Plane For 6 MV FFF Plan 
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Table 3.11 6 MV FFF Plan 2D Gamma Index Results, UAB 
Plan: 6 MV FFF, UAB, TrueBeam STx 
Phantom Irrad.№ 
Gamma Index 
Analysis 
Criteria 
Orthogonal Plane Passing Rate, % Average 
3-planes, 
% 
Standard 
Deviation 
3-planes Axial Coronal Sagittal 
1 
±5%/3mm 92.3% 97.0% 92.8% 94.0% 2.58% 
±8%/3mm 99.9% 99.9% 99.2% 99.7% 0.39% 
2 
±5%/3mm 96.5% 97.2% 88.9% 94.2% 4.62% 
±8%/3mm 99.7% 99.8% 96.4% 98.6% 1.92% 
3 
±5%/3mm 92.2% 96.3% 90.0% 92.8% 3.22% 
±8%/3mm 97.4% 99.6% 96.7% 97.9% 1.50% 
Ave.Passing Rate 
– All Irradiations, 
% 
±5%/3mm 93.7% 96.8% 90.5% 93.7% 
 
±8%/3mm 99.0% 99.8% 97.44% 98.7% 
Std Deviation – 
All Irradiations, 
% 
±5%/3mm 2.47% 0.47% 2.01% 0.75% 
±8%/3mm 1.36% 0.18% 1.55% 0.89% 
 
A plot of the data in the Table 3.11 is presented in Figures 3.61-3.62. Error bars represent the 95% 
CI. 
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Figure 3.61 2D Gamma Index Results Using ±5%/3mm Criteria For 6 MV FFF Plan 
 
Figure 3.62 2D Gamma Index Results Using ±8%/3mm Criteria For 6 MV FFF Plan 
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3.3.3.4 Dose Profiles Results 
The example of Right-Left, Anterior-Posterior, and Superior-Inferior measured (film) and 
calculated (TPS) profiles for the first irradiation of the phantom in UAB Medical Center using the 6 
MV FFF 3D SBRT plan are shown in Figures 3.63-3.65. Plane specific profiles for other irradiations 
and their corresponding TLD doses are presented in the Appendix. 
 
Figure 3.63 Right-Left Profiles In Axial And Coronal Planes Compared To The Calculated Dose Profiles 
For 6 MV FFF Plan 
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Figure 3.64 Anterior-Posterior Profiles In Axial And Sagittal Planes Compared To The Calculated Dose 
Profiles For 6 MV FFF Plan 
 
Figure 3.65 Superior-Inferior Profiles In Coronal And Sagittal Planes Compared To The Calculated 
Dose Profiles For 6 MV FFF Plan 
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3.3.4 UAB: 3D SBRT 10 MV FFF Plan 
3.3.4.1 Plan Details  
Figure 3.66 represents a 3-plane view of the tumor and the calculated isodose map. 
Calculated dose demonstrates a good conformality in all three planes. A magnified view of the same 
axial plane is shown in Figure 3.67. 
 
Figure 3.66 3-Plane View Of The Tumor And The Isodose Map 
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Figure 3.67 A Magnified Axial Plane View Of The Tumor And The Isodose Map 
 
Figure 3.68 shows a Dose Volume Histogram for the calculated dose distribution. As with 
previously discussed treatment plans the radiation doses to non-tumor tissues such as lung, heart, and 
spine were substantially lower than the established RTOG and RPC limits while the tumor was 
covered according to the prescribed dose. 
92 
 
 
Figure 3.68 10MV FFF 3D SBRT Plan – Dose Volume Histogram 
3.3.4.2 Target TLD Results  
Table 3.12 shows superior and inferior target TLD data corrected for daily output and Figure 
3.69 displays measured-to-predicted dose ratios for target TLDs. The averages have error bars 
representing the 95% confidence interval (CI) plotted as well.  
Table 3.12 Target TLD Results. 10 MV FFF, UAB 
Plan: 10 MV FFF, UAB, TrueBeam STx 
Phantom 
Irradiation 
№ 
TLD Dose, Gy 
Daily 
Output 
Correction 
Corrected TLD Dose, 
Gy 
Eclipse Calculated 
Dose, Gy 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
PTV 
TLD_sup 
PTV 
TLD_inf 
1 8.5267 8.3748 
0.991 
8.6043 8.5551 
8.776 8.750 2 8.6347 8.4756 8.7132 8.5526 
3 8.4064 8.3074 8.4828 8.3829 
Average 8.6001 8.4969 8763 
Measured/Predicted Ratio 0.980 0.971 0.976 
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Figure 3.69 Measured-To-Predicted Dose Ratios Of Target TLDs For 10 MV FFF Plan (UAB MC) 
3.3.4.3 2D Gamma Index Analysis Results  
Figures 3.70-3.72 show examples of 2D gamma index results for one of the irradiations of 
the phantom in UAB Medical Center using the 10 MV FFF 3D SBRT plan and ±5%/3mm criteria. 
Gamma analysis results using a ±8%/3mm criteria, as well as results for other irradiations are 
presented in the Appendix.  
Table 3.13 summarizes 2D gamma index results for all three irradiations (using the 10 MV 
FFF plan) of the RPC phantom at University of Alabama at Birmingham.  
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Figure 3.70 2D Gamma Index Results: ±5%/3mm, Axial Plane For 10 MV FFF Plan 
 
 
Figure 3.71 2D Gamma Index Results: ±5%/3mm, Coronal Plane For 10 MV FFF Plan 
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Figure 3.72 2D Gamma Index Results: ±5%/3mm, Sagittal Plane For 10 MV FFF Plan 
Table 3.13 10 MV FFF Plan 2D Gamma Index Results, UAB 
Plan: 10 MV FFF, UAB, TrueBeam STx 
Phantom Irrad.№ 
Gamma Index 
Analysis 
Criteria 
Orthogonal Plane Passing Rate, % Average 
3-planes, 
% 
Standard 
Deviation 
3-planes Axial Coronal Sagittal 
1 
±5%/3mm 97.1% 98.2% 97.3% 97.5% 0.59% 
±8%/3mm 99.2% 99.9% 99.6% 99.5% 0.36% 
2 
±5%/3mm 99.3% 95.2% 96.5% 97.0% 2.06% 
±8%/3mm 99.9% 99.9% 99.9% 99.9% 0.01% 
3 
±5%/3mm 91.2% 98.8% 93.5% 94.5% 3.90% 
±8%/3mm 96.2% 99.9% 98.4% 98.2% 1.85% 
Ave.Passing Rate 
– All Irradiations, 
% 
±5%/3mm 95.8% 97.4% 95.8% 96.3% 
 
±8%/3mm 98.4% 99.9% 99.3% 99.2% 
Std Deviation – 
All Irradiations, 
% 
±5%/3mm 4.20% 1.89% 2.01% 1.63% 
±8%/3mm 1.95% 0.00% 0.80% 0.92% 
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A plot of the data in the Table 3.13 is presented in Figures 3.73-3.74. Error bars represent the 95% 
CI. 
Figure 3.73 2D Gamma Index Results Using ±5%/3mm Criteria For 10 MV FFF Plan 
Figure 3.74 2D Gamma Index Results Using ±8%/3mm Criteria For 10 MV FFF Plan 
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3.3.4.4 Dose Profiles Results 
The example of Right-Left, Anterior-Posterior, and Superior-Inferior measured (film) and 
calculated (TPS) profiles for the first irradiation of the phantom in the UAB Medical Center using 
the 10 MV FFF 3D SBRT plan are shown in Figures 3.75-3.77. Plane specific profiles for other 
irradiations and their corresponding TLD doses are presented in the Appendix. 
 
Figure 3.75 Right-Left Profiles In Axial And Coronal Planes Compared To The Calculated Dose Profiles 
For 10 MV FFF Plan 
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Figure 3.76 Anterior-Posterior Profiles In Axial And Sagittal Planes Compared To The Calculated Dose 
Profiles For 10 MV FFF Plan 
 
Figure 3.77 Superior-Inferior Profiles In Coronal And Sagittal Planes Compared To The Calculated 
Dose Profiles For 10 MV FFF Plan 
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3.4 Results Discussion 
All three 6 MV/6 MV FFF 3D SBRT plans that were, delivered at MD Anderson Cancer 
Center and at the University of Alabama Medical Center resulted in a good agreement of point dose, 
between that measured by the TLDs, and that calculated in the Eclipse TPS. The average 
measured/predicted ratio for both target TLDs was 0.971 for 6MV MDA and 0.957/0.957 for 6 
MV/6 MV FFF UAB, respectively. This represents measured dose of 2.9% and 4.3% lower than was 
expected based on the calculations. At the same time both results are in excellent agreement with the 
RPC expected dose ratio of 0.96-0.97 [8, 9] and are within the ±5% of the calculated dose limit 
established in this work. 
2D gamma index analysis for these three plans resulted in 96.3%/95.6%/93.7% average 
pixels passing rate over all planes using ±5%/3mm, and 99.8%/99.4%/98.7% using ±8%/3mm 
criteria for MDA 6 MV 3D SBRT, UAB 6 MV 3D SBRT and UAB 6 MV FFF 3D SBRT plans, 
respectively. In this work the lower limit for passing rate using ±5%/3mm criteria was established at 
90% average for all planes while the lower limit for gamma index established by RPC in their 
credentialing procedures is set to 85% using ±5%/5mm around 0.97.  
Dose profile analysis revealed a good agreement between calculated and measured data. Due 
to phantom alignment uncertainties there was a ~2mm profile shift to the right on coronal films, and 
~2mm posterior and ~1mm inferior shift on sagittal films in an MDA plan. UAB plans had a similar 
~1-2mm profile shift to the right on coronal films and ~2mm anterior and inferior profile shifts on 
sagittal films. This misalignment resulted in a minor profile mismatch and in slightly higher standard 
deviation for these planes. 
These results show that 6 MV 3D SBRT plans delivered at both institutions were 
comparable in respect to absolute point dose, as well as 2D planar dose distribution, and are well 
within the official RPC limits and the limits established in this work. 
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The 10 MV FFF 3D SBRT plan point dose measured by the TLDs was also in a good 
agreement with predicted dose that was calculated in Eclipse TPS with an average 
measured/predicted ratio for both target TLDs of 0.976 which is slightly higher than the ratio 
obtained in the 6MV plans. This represents measured dose of 2.4% less than was expected and is in 
excellent agreement with the RPC expected dose ratio of 0.97, as well as is well within ±5% of the 
calculated dose.  
2D gamma index analysis resulted in 96.3% and 99.2% average passing rates using over all 
planes using ±5%/3mm and ±8%/3mm criteria respectively. This agreement was comparable to the 6 
MV plans, as well as passing both 90% and 85% limits established in his work and by the RPC, 
respectively. As with 6 MV, 10 MV FFF measured dose profiles were in a good agreement with the 
calculated data.  
Analysis of the higher energy, 15 MV and 18 MV, 3D SBRT plans revealed that point doses 
measured by the TLDs resulted in the average measured/predicted dose ratios for both target TLDs 
of 0.995 for 15 MV and 1.025 for 18 MV. Both ratios are in a good agreement with predicted dose 
calculated in Eclipse TPS. This represents measured dose of 0.5% lower and 2.5% greater than was 
expected. 15 MV ratio of 0.995 is slightly higher than the RPC expected dose ratio of 0.97, but it is 
still within 0.92-1.02 passing range, while the 18 MV dose ratio of 1.025 falls slightly outside the 
maximum limit of 1.02 allowed by the RPC. At the same time both the 15 MV and 18 MV, 
measured/predicted point dose ratios are within the criteria of this work of ±5% of the calculated 
dose. Care should be taken when considering the RPC limits for energies higher than 12 MV. Since 
the original RPC criteria was established based on the statistical analysis of the large number 
irradiations in 6-12 MV range [8, 9], its validity has not been verified for energies greater than 12 
MV. 
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2D gamma index analysis for both plans resulted in 97.4%/ 92.2% average passing rate over 
all planes using ±5%/3mm and 99.9%/99.9% using ±8%/3mm for 15 and 18 MV, respectively. This 
agreement passes both the 90% and 85% limits established in his work and by the RPC for their 
credentialing process, respectively.  
Dose profile analysis revealed a good agreement between calculated and measured data. 
Small phantom misalignments were observed: a ~1-2mm profile shift to the right on coronal films 
and ~2mm anterior and inferior on sagittal films in 15 MV plan, and a similar ~2mm profile shift to 
the right on coronal and axial films in the 18 MV plan. This resulted in lower gamma index results 
for coronal planes and subsequently higher standard deviations for these three planes’ averages in the 
18 MV plan and in slightly higher standard deviation for the sagittal plane in the 15 MV plan. 
Further examination of 1D dose profiles reveals a noticeable divergence of the measured 
profiles from the calculated outside the planning treatment volume in superior-inferior direction for 
all plans and beam energies. This deviation represents an increased dose to the tissues outside the 
planned treatment volume and a higher dose to a normal lung by 4-5% of the prescribed dose than 
what was predicted by the AAA calculation in the Eclipse TPS. Since the gamma index analysis was 
performed on PTV+2 cm this disagreement could be identified as failing points (yellow and red) on 
some of the coronal and sagittal gamma index maps outside the superior and inferior edges of the 
PTV. This region is characterized by the multi-leaf collimators covering larger field and is a subject 
of the increased beam penumbra.  
Plotting the TLD data for all plans and calculating linear regression fit shows that the 
increase in beam energy results in a corresponding increase in the measured-to-predicted dose ratio 
of 0.005 MV
-1
 or 0.5% change in ratio for every 1 MV change in beam energy (Figure 3.78). 
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Figure 3.78 Measured-to-Predicted Dose Ratio vs Beam Energy 
 
This dependency agrees with the RPC statistical data for lower beam energies, and also 
predicts that 15 MV energy plans calculated using AAA heterogeneity correction would result in the 
most accurate delivered dose with measured-to-calculated dose ratio of 1.00. 
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Chapter 4 Conclusion 
 
4.1 General  
Papanikolau et al do not recommend the use of beam energies higher than 12 MV for 
treatment of tumors surrounded by lung tissue inside the thorax due to the insufficient heterogeneity 
correction of existing dose calculation algorithms for high energies and small field sizes [7]. In this 
work the effectiveness of Anisotropic Analytical Algorithm for high energy flattened and flattening-
filter-free beams has been evaluated using the Radiological Physics Center Lung phantom.  
The verification of the dose calculation by the Varian, Inc. superposition-convolution AAA 
algorithm for tumor located in the middle of the lung was performed for the range of x-ray energies 
and beam types that are currently used in radiation therapy. Six stereotactic radiation body therapy 
treatment plans were designed in the Varian Eclipse treatment planning system using dose 
prescriptions and constraints that are identical to the RPC’s credentialing requirements using thorax 
anthropomorphic phantom. Each plan was normalized that so at least 95% of PTV volume would 
receive 100% of prescribed dose. Prior to delivery, all plans were reviewed for the compliance with 
the current RPC accreditation guidelines as well as with the existing clinical trials recommendations 
by the Radiation Therapy Oncology Group [15-18]. Since the current guidelines limit the maximum 
photon energy to not greater than 12 MV [7], some of the existing metrics may not be applicable to 
higher energy beams, i.e. 15 MV and 18 MV.  
In this work the point doses measurements were performed using TLD and the two-
dimensional dose distributions were obtained from analyzing EBT2 radiochromic films. The primary 
acceptance criteria were specified in the research design of this work for the 2D dose distribution as 
90% of points on average passing ±5% or 3mm distance to agreement and the measured point doses 
being within ±5% of the calculated dose.  
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For the credentialing process of the institutions the RPC has implemented the following 
acceptance criteria: 0.92-1.02 for measured-to-predicted point dose ratio, ≥80% of single plane 
≥85% three-plane average points passing ±5%/5mm gamma criteria. The latter criteria are calculated 
by the RPC around 0.97 which would effectively correspond to ±8%/5mm around 1.0 using this 
work’s methodology. To make a comparison of the experimental data with the RPC action limits the 
secondary set of criteria was adopted. In addition to the primary criteria of 0.95-1.05 and ±5%/3mm, 
the analyzed data was also compared with the existing 0.92-1.02 point dose RPC limits and a more 
stringent gamma index of ≥90% three-plane average points passing ±8%/3mm. 
The three irradiation averaged TLD point dose measurements for all six plans are plotted in 
Figure 4.1.  
 
Figure 4.1 Measured-To-Predicted TLD Dose Ratios, 3-Irradiation Per Plan Average 
 
The results demonstrate that all plans meet the passing criteria of ±5% of the calculated 
absolute dose, as well as the RPC criteria of 0.97±0.05 with one exception. The average measured-
RPC Limits 
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to-predicted ratio of the TLD doses delivered using 18 MV beam energy was calculated to be 1.025, 
which is below the maximum limit of 1.05 established in this work. This number falls slightly 
outside the 1.02 which is the maximum ratio allowed by the RPC. As was mentioned earlier in 
chapter 3.4, the 0.92-1.02 range (or 0.97±0.05) point dose criterion was established by the RPC 
based on the multi institutional data to maintain consistency among different clinical trials. However, 
as most clinical trial protocols recommend the use of photon beam energies of less than 12 MV, this 
RPC limit should only be applied to plans designed and delivered according with these protocols 
recommendations, i.e. using beam energies in the 6-12 MV range. No criteria currently exist in the 
RPC regarding point dose limits for energies greater than 12 MV; therefore, the existing limits may 
not be applicable in this case. 
Followill et al, in their recent study [9] report that for Monte Carlo based methods new 
acceptance criterion of 1±0.05 for measured-to-predicted dose ratio will be used. This is the same 
passing criterion that was used in this work and that were successfully passed by all delivered plans 
(range 0.957-1.025). Acceptance of this new criterion not only for treatment plans calculated using 
Monte Carlo based methods, but for all other currently available clinical systems would make it 
easier to compare the dose calculation accuracy and effectiveness of different methods and 
algorithms. On the other hand, changing the acceptance criteria would create a substantial problem 
regarding consistency of clinical trials. Since all historical data was collected and processed using the 
0.97±0.05 criterion it would require recalculation of all previously acquired data and possibly even 
changing the new acceptance criterion of 1.0±0.05 itself. 
The gamma index analysis of the 2D dose distribution shows that 90% or more points on 
average have passed the ±5%/3mm criteria for all delivered plans with the lowest being 92.2% for 
the 18MV plan and the highest being 97.4% for the 15MV plan. The 18 MV number was the result 
of lower gamma indices for coronal planes in all three irradiations. Figure 4.2 shows a three 
irradiation averaged summary of gamma index analysis using ±5%/3mm criteria for all six plans. 
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Figure 4.2 Plot Of Averaged Points Passing ±5%/3mm Criteria 2D Gamma Analysis For All Plans 
 
The gamma index analysis data using secondary criteria of ±8%/3mm is presented in Figure 
4.3. All plans showed an excellent agreement with calculated dose distributions with the lowest 
being 98.7% of points passing ±8%/3mm for the 6MV FFF plan and the highest being 99.9% for the 
15 MV plan. As was mentioned earlier the ±8%/3mm criteria were included to compare the plans 
developed in this work with the RPC standards. Although, this criteria is more stringent than the 
existing limits it still provides the means to evaluate and compare these plans to the currently 
existing credentialing standards. Since the RPC criteria were developed based on the existing 
recommendations for maximum beam energy of 12 MV, the comparison of the gamma indices 
calculated using ±8%/3mm criteria with the RPC data should be done only for plans using 6 and 10 
MV beams. The results of 2D dose distribution analysis for 15 and 18MV plans using such criteria 
may not be valid, despite showing an excellent agreement.  
Passing 
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Figure 4.3 Plot Of Averaged Points Passing ±8%/3mm Criteria 2D Gamma Analysis For All Plans 
 
The one dimensional dose profile analysis revealed a good agreement for all three 
orthogonal planes. There were occasional 2-3 mm shifts in some planes that resulted in displacement 
of the measured dose profiles relatively to the calculated profiles and hence in the lower 
corresponding gamma indices. Proper phantom alignment could further improve these results.  
The results from both flattened and flattening-filter-free plans in 6-10 MV range are in a 
good agreement with the RPC data [8, 9, 29] and show that AAA algorithm is capable of calculating 
treatment plans in a complex heterogeneous environment consistently and accurately using 
±5%/3mm gamma index and ±5% point dose criteria. This concurs with the existing 
recommendations of using beams energies of not greater than 12 MV for lung treatments [7]. 
Regarding the higher energies, neither 15 MV nor 18 MV are typically used in radiation 
therapy treatments of lung tumors due to the substantial loss of electronic equilibrium and a larger 
penumbra as reported by Wang et al [10]. Klein et al reported that plans using 18 MV can underdose 
the tumor by up to 11% [5] which can significantly compromise the effectiveness of the radiation 
RPC Limit 
108 
 
treatment and local tumor control. Studies that specifically looked into the AAA dose calculation 
effectiveness in heterogeneous environment also reported larger standard deviation with plans using 
18 MV (up to 8%) as compared to 6 MV [13]. 
Analyzed data from 15 MV and 18 MV plans calculated in Eclipse TPS using AAA v. 8.9.08 
delivered to the RPC anthropomorphic lung phantom shows a very good agreement between the 
calculated and delivered doses. While there is an increased electronic lateral disequilibrium and a 
larger penumbra for higher energies, both 15 MV and 18 MV 3D SBRT plans calculated with AAA 
do not show a decreased dose to the tumor or notably higher standard deviations for these energies. 
In fact, plans calculated using AAA with higher energies resulted in a higher overall dose to the 
tumor as compared to the lower energies in 6-10 MV range, as was mentioned in Results Discussion 
(chapter 3.4). This increase in dose to the tumor with increased energy does not concur with these 
published studies. 
This disagreement could stem from the fact that that recent changes in AAA, such as better 
Monte Carlo pre-calculated kernels as well in algorithm itself, made it able to account for these 
effects. The results obtained from analyzing this work’s data show that delivered 3D SBRT plans 
calculated using Analytical Anisotropic Algorithm with different beams (flattened and flattening-
filter-free) and different energies (6 MV – 18 MV) result in measured doses that are within ±5% of 
the calculated dose, as well as 90% or more pixels are passing the ±5% dose or 3 mm distance to 
agreement using 2D gamma index analysis. This demonstrates that AAA implemented in Eclipse 
TPS is fully capable of calculating treatment doses in heterogeneous medium, such as lung, using 
both lower and higher photon beam energies.   
4.2 Future Work  
In this work the effectiveness of the 3D superposition-convolution AAA algorithm with high 
energies was evaluated using stereotactic radiation body therapy plans. To simplify the data analysis 
109 
 
and identify the potential deficiencies of the AAA algorithm all developed and delivered plans used 
only static beams. Advanced radiation therapy treatment techniques, such as Intensity Modulated and 
Arc Radiation Therapy extensively use the MLC to modulate the dose. The continuous changes in 
MLC leaf position while delivering the high energy dose may pose a challenge to the AAA 
algorithm due to penumbra broadening of the beam. 
The RPC anthropomorphic phantom used in this study was stationary to eliminate any 
alignment uncertainties due to target movement. During the breathing cycle, respiratory motion of 
the thorax may result in a sizable displacement of a tumor which could negatively affect the tumor 
coverage. In order to evaluate the dose delivery with tumor motion the RPC phantom can be placed 
on the moving platform that was specifically designed to simulate such motion. A 4D computed 
tomography simulation along with the treatment plan that takes into account this motion would help 
to evaluate the effectiveness of the AAA algorithm in a more realistic condition.       
Finally, Acuros XB dose calculation algorithm was recently introduced by Varian, Inc to be 
implemented in Eclipse TPS. This new algorithm could lead to an increased accuracy of the dose 
calculation as compared to the currently used 3D pencil beam superposition-convolution algorithms 
such as AAA. 
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Chapter 5 Appendix 
 
5.1 6 MV SBRT MD Anderson CANCER CENTER 2D Gamma Index Maps and 
Dose Profiles 
 
Figure 5.1 6 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #1 
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Figure 5.2 6 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #1 
 
 
Figure 5.3 6 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #1 
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Figure 5.4 6 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #1 
 
 
Figure 5.5 6 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #1 
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Figure 5.6 6 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #1 
 
 
Figure 5.7 6 MV SBRT MDA 1D Right-Left Dose Profiles: Irradiation #1 
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Figure 5.8 6 MV SBRT MDA 1D Anterior-Posterior Dose Profiles: Irradiation #1 
 
Figure 5.9 6 MV SBRT MDA 1D Superior-Inferior Dose Profiles: Irradiation #1 
115 
 
 
Figure 5.10 6 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #2 
 
 
Figure 5.11 6 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #2 
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Figure 5.12 6 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #2 
 
 
Figure 5.13 6 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #2 
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Figure 5.14 6 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #2 
 
 
Figure 5.15 6 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #2 
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Figure 5.16 6 MV SBRT MDA 1D Right-Left Dose Profiles: Irradiation #2 
 
Figure 5.17 6 MV SBRT MDA 1D Anterior-Posterior Dose Profiles: Irradiation #2 
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Figure 5.18 6 MV SBRT MDA 1D Superior-Inferior Dose Profiles: Irradiation #2 
 
 
Figure 5.19 6 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #3 
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Figure 5.20 6 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #3 
 
 
Figure 5.21 6 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #3 
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Figure 5.22 6 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #3 
 
 
Figure 5.23 6 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #3 
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Figure 5.24 6 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #3 
 
 
Figure 5.25 6 MV SBRT MDA 1D Right-Left Dose Profiles: Irradiation #3 
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Figure 5.26 6 MV SBRT MDA 1D Anterior-Posterior Dose Profiles: Irradiation #3 
 
Figure 5.27 6 MV SBRT MDA 1D Superior-Inferior Dose Profiles: Irradiation #3 
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5.2 18 MV SBRT MD Anderson CANCER CENTER 2D Gamma Index Maps and 
Dose Profiles 
 
Figure 5.28 18 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #1 
 
Figure 5.29 18 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #1 
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Figure 5.30 18 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #1 
 
 
Figure 5.31 18 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #1 
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Figure 5.32 18 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #1 
 
 
Figure 5.33 18 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #1 
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Figure 5.34 18 MV SBRT MDA 1D Right-Left Dose Profiles: Irradiation #1 
 
Figure 5.35 18 MV SBRT MDA 1D Anterior-Posterior Dose Profiles: Irradiation #1 
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Figure 5.36 18 MV SBRT MDA 1D Superior-Inferior Dose Profiles: Irradiation #1 
 
 
Figure 5.37 18 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #2 
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Figure 5.38 18 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #2 
 
 
Figure 5.39 18 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #2 
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Figure 5.40 18 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #2 
 
 
Figure 5.41 18 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #2 
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Figure 5.42 18 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #2 
 
 
Figure 5.43 18 MV SBRT MDA 1D Right-Left Dose Profiles: Irradiation #2 
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Figure 5.44 18 MV SBRT MDA 1D Anterior-Posterior Dose Profiles: Irradiation #2 
 
Figure 5.45 18 MV SBRT MDA 1D Superior-Inferior Dose Profiles: Irradiation #2 
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Figure 5.46 18 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #3 
 
 
Figure 5.47 18 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #3 
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Figure 5.48 18 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #3 
 
 
Figure 5.49 18 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #3 
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Figure 5.50 18 MV SBRT MDA 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #3 
 
 
Figure 5.51 18 MV SBRT MDA 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #3 
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Figure 5.52 18 MV SBRT MDA 1D Right-Left Dose Profiles: Irradiation #3 
 
Figure 5.53 18 MV SBRT MDA 1D Anterior-Posterior Dose Profiles: Irradiation #3 
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Figure 5.54 18 MV SBRT MDA 1D Superior-Inferior Dose Profiles: Irradiation #3 
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5.3 6 MV SBRT University of Alabama MEDICAL CENTER 2D Gamma Index 
Maps and Dose Profiles 
 
Figure 5.55 6 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #1 
 
Figure 5.56 6 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #1 
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Figure 5.57 6 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #1 
 
 
Figure 5.58 6 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #1 
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Figure 5.59 6 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #1 
 
 
Figure 5.60 6 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #1 
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Figure 5.61 6 MV SBRT UAB 1D Right-Left Dose Profiles: Irradiation #1 
 
Figure 5.62 6 MV SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #1 
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Figure 5.63 6 MV SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #1 
 
 
Figure 5.64 6 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #2 
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Figure 5.65 6 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #2 
 
 
Figure 5.66 6 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #2 
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Figure 5.67 6 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #2 
 
 
Figure 5.68 6 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #2 
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Figure 5.69 6 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #2 
 
 
Figure 5.70 6 MV SBRT UAB 1D Right-Left Dose Profiles: Irradiation #2 
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Figure 5.71 6 MV SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #2 
 
Figure 5.72 6 MV SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #2 
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Figure 5.73 6 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #3 
 
 
Figure 5.74 6 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #3 
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Figure 5.75 6 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #3 
 
 
Figure 5.76 6 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #3 
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Figure 5.77 6 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #3 
 
 
Figure 5.78 6 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #3 
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Figure 5.79 6 MV SBRT UAB 1D Right-Left Dose Profiles: Irradiation #3 
 
Figure 5.80 6 MV SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #1 
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Figure 5.81 6 MV SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #1 
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5.4 15 MV SBRT University of Alabama MEDICAL CENTER 2D Gamma Index 
Maps and Dose Profiles 
 
Figure 5.82 15 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #1 
 
Figure 5.83 15 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #1 
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Figure 5.84  15 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #1 
 
 
Figure 5.85 15 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #1 
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Figure 5.86 15 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #1 
 
 
Figure 5.87 15 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #1 
155 
 
 
Figure 5.88 15 MV SBRT UAB 1D Right-Left Dose Profiles: Irradiation #1 
 
Figure 5.89 15 MV SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #1 
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Figure 5.90 15 MV SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #1 
 
 
Figure 5.91 15 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #2 
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Figure 5.92 15 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #2 
 
 
Figure 5.93 15 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #2 
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Figure 5.94 15 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #2 
 
 
Figure 5.95 15 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #2 
159 
 
 
Figure 5.96 15 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #2 
 
 
Figure 5.97 15 MV SBRT UAB 1D Right-Left Dose Profiles: Irradiation #2 
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Figure 5.98 15 MV SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #2 
 
Figure 5.99 15 MV SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #2 
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Figure 5.100 15 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #3 
 
 
Figure 5.101 15 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #3 
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Figure 5.102 15 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #3 
 
 
Figure 5.103 15 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #3 
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Figure 5.104 15 MV SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #3 
 
 
Figure 5.105 15 MV SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #3 
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Figure 5.106 15 MV SBRT UAB 1D Right-Left Dose Profiles: Irradiation #3 
 
Figure 5.107 15 MV SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #3 
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Figure 5.108 15 MV SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #3 
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5.5 6 MV FFF SBRT University of Alabama MEDICAL CENTER 2D Gamma Index 
Maps and Dose Profiles 
 
Figure 5.109 6 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #1 
 
Figure 5.110 6 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #1 
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Figure 5.111 6 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #1 
 
 
Figure 5.112 6 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #1 
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Figure 5.113 6 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #1 
 
 
Figure 5.114 6 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #1 
 
169 
 
 
Figure 5.115 6 MV FFF SBRT UAB 1D Right-Left Dose Profiles: Irradiation #1 
 
Figure 5.116 6 MV FFF SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #1 
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Figure 5.117 6 MV FFF SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #1 
 
 
Figure 5.118 6 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #2 
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Figure 5.119 6 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #2 
 
 
Figure 5.120 6 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #2 
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Figure 5.121 6 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #2 
 
 
Figure 5.122 6 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #2 
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Figure 5.123 6 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #2 
 
 
Figure 5.124 6 MV FFF SBRT UAB 1D Right-Left Dose Profiles: Irradiation #2 
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Figure 5.125 6 MV FFF SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #2 
 
Figure 5.126 6 MV FFF SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #2 
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Figure 5.127 6 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #3 
 
 
Figure 5.128 6 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #3 
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Figure 5.129 6 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #3 
 
 
Figure 5.130 6 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #3 
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Figure 5.131 6 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #3 
 
 
Figure 5.132 6 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #3 
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Figure 5.133 6 MV FFF SBRT UAB 1D Right-Left Dose Profiles: Irradiation #3 
 
Figure 5.134 6 MV FFF SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #3 
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Figure 5.135 6 MV FFF SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #3 
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5.6 10 MV FFF SBRT University of Alabama MEDICAL CENTER 2D Gamma 
Index Maps and Dose Profiles 
 
Figure 5.136 10 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #1 
 
Figure 5.137 10 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #1 
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Figure 5.138 10 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #1 
 
 
Figure 5.139 10 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #1 
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Figure 5.140 10 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #1 
 
 
Figure 5.141 10 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #1 
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Figure 5.142 10 MV FFF SBRT UAB 1D Right-Left Dose Profiles: Irradiation #1 
 
Figure 5.143 10 MV FFF SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #1 
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Figure 5.144 10 MV FFF SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #1 
 
 
Figure 5.145 10 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #2 
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Figure 5.146 10 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #2 
 
 
Figure 5.147 10 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #2 
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Figure 5.148 10 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #2 
 
 
Figure 5.149 10 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #2 
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Figure 5.150 10 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #2 
 
 
Figure 5.151 10 MV FFF SBRT UAB 1D Right-Left Dose Profiles: Irradiation #2 
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Figure 5.152 10 MV FFF SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #2 
 
Figure 5.153 10 MV FFF SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #2 
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Figure 5.154 10 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Axial Plane, Irradiation #3 
 
 
Figure 5.155 10 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Axial Plane, Irradiation #3 
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Figure 5.156 10 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Coronal Plane, Irradiation #3 
 
 
Figure 5.157 10 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Coronal Plane, Irradiation #3 
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Figure 5.158 10 MV FFF SBRT UAB 2D Gamma Index Results: ±5%/3mm, Sagittal Plane, Irradiation #3 
 
 
Figure 5.159 10 MV FFF SBRT UAB 2D Gamma Index Results: ±8%/3mm, Sagittal Plane, Irradiation #3 
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Figure 5.160 10 MV FFF SBRT UAB 1D Right-Left Dose Profiles: Irradiation #3 
 
Figure 5.161 10 MV FFF SBRT UAB 1D Anterior-Posterior Dose Profiles: Irradiation #3 
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Figure 5.162 10 MV FFF SBRT UAB 1D Superior-Inferior Dose Profiles: Irradiation #3 
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